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ABSTRACT
The main objectives of this dissertation were to quantitatively assess
whether there is an association between medications (e.g., antibiotics, PPIs,
antipsychotics) and cognitive performance over time, conduct a causal mediation
analysis to evaluate the role of inflammation (C-reactive protein) in the
association between medications and subsequent cognitive decline, and
examine if dysbiosis-related medications (DRM) are associated with a greater
risk of dementia for participants that were cognitively normal and had MCI at
baseline.
The Health and Retirement Study (HRS) was used to conduct a
secondary data analysis that used longitudinal data from 2004 to 2016. The HRS
is an ongoing, nationally representative prospective sample of individuals aged
50 years and older interviewed biannually since 1992. Beginning in 2005, the
Prescription Drug Study was initiated, which captured usage of prescription
medications. Additionally, in 2006, HRS began conducting enhanced face-to-face
interviews, which included information on C-reactive protein as a marker of
inflammation.
Chapter 4 examined the longitudinal association of specific DRM and
grouped medications with cognitive performance over time. Our results showed
that SSRI antidepressants, antipsychotics, antihistamines, and taking multiple
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medications were associated with worsening cognitive changes. Chapter 5
provided a more in-depth picture by which DRM may be associated with
cognitive scores by understanding if inflammation mediates the association
between DRM and cognitive scores. Our study did not provide any statistically
significant results. Finally, chapter 6 explored how medications may differentially
impact the association of those that were cognitively normal and had MCI at
baseline with having dementia. This chapter found evidence that those who had
MCI and were taking two or more medications had greater odds of dementia;
however, these odds decreased over time compared to those not taking
dysbiosis-related medications.
While these findings provide evidence to support and expand the current
knowledge, it is critical to understand further how DRM may impact the gut
microbiome over time and how these changes may be associated with cognitive
changes. Future research should aim to understand how medications and their
combinations directly impact the gut microbiome and how these changes may
influence cognitive changes over time, specifically those in mid-to-late-life.
Keywords: cognitive decline, mild cognitive impairment, dementia,
medications, microbiome, dysbiosis
.
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CHAPTER 1
INTRODUCTION
Over 5 million Americans have Alzheimer’s disease and related dementias
(ADRD),1 while roughly 2.4 million have preclinical ADRD or mild cognitive
impairment (MCI).2 With anticipated growth of the older adult population, the
prevalence of ADRD is expected to triple by 2060,3 which will translate to
increased direct and indirect costs expected to exceed $1.2 trillion in the US.4
Identifying potential risk factors of ADRD can delay or may even prevent cases.
Through identification of these high-risk individuals and providing early
intervention, the onset of ADRD may be delayed –– which has the potential to
reduce both the prevalence and costs of ADRD by 40%. 5
One growing area of research is the influence of the gut microbiome on
human health and development. The gut microbiome, a collection of thousands
of species of microorganisms harbored within the human body, 6 has been found
to be associated with many diseases, including cognitive decline, MCI, and
ADRD. A healthy gut microbiome performs many functions important for human
health, such as energy extraction, the breakdown of vitamins, protection against
pathogen overgrowth, and immune system regulation. 7 However, disruptions of
healthy gut microbiota – also known as dysbiosis – can have negative health
impacts. Dysbiosis may be caused by medications (e.g., antibiotics, proton-pump
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inhibitors), stress, diet, or other factors and has been found to be associated with
obesity, asthma, and Crohn’s disease. 8–10 Researchers also have examined the
association between dysbiosis and neurodegenerative diseases, such as
Parkinson’s11 and Alzheimer’s Disease;12 however, the role of the gut
microbiome in the development and progression of these diseases is still not fully
understood. Previous research has found that dysbiosis can cause a
phenomenon called “leaky gut,” where the disruption of the normal gut flora
allows bacteria from the gut to enter the bloodstream. 13 Additionally, the bloodbrain-barrier becomes more permeable due to dysbiosis, allowing bacteria from
the gut to enter the brain and compromise mental health. 13,14 These alterations
can: 1) increase inflammation in the brain, which has been associated with
cognitive decline, MCI, and ADRD;15,16 and 2) promote formation and
accumulation of beta amyloid which is a hallmark of AD.17
Antibiotics as a risk factor for dysbiosis has been well established, but
recent studies have found commonly used drugs are associated with altering the
gut microbiome.9,18 A recent study found that Proton pump inhibitors (PPIs), used
to reduce stomach acid production, was associated with a change in a large
amount of microbial taxa and pathways.9 Antipsychotics medications, specifically
second-generation, has been associated with increasing bacteria are related to
inflammation and obesity.19 Further, recent studies in the general population
showed many other medications, include commonly used medications, were
associated with changes in the gut microbiome composition. 9,20 Although these
drugs are known to be associated with dysbiosis and human health, a better

2

understanding of the longitudinal association on cognition, cognitive impairment,
and dementia is needed.
1.1 AIMS AND HYPOTHESIS
The overall goal of this investigation is to evaluate the relationship
between medications associated with dysbiosis, cognitive decline, and transition
from cognitively normal or MCI to ADRD among older US adults. This project will
use longitudinal data over an 12-year period (2004-2016) from the Health and
Retirement Study (HRS), an ongoing, nationally representative cohort study of
older US adults, while linking to the Prescription Drug Study (PDS) – a subset of
HRS - to obtain information on medications. The Specific Aims of this project
are:
Aim 1. Quantitatively assess whether there is an association between
medications (e.g., antibiotics, PPIs, antipsychotics) and cognitive performance
over time.
Hypothesis: Individuals using medications associated with dysbiosis will
experience a greater decrease in cognitive scores and will be more likely to be
categorized as MCI or dementia over an 12-year follow up compared to
individuals not using those medications.
Aim 2. Conduct a causal mediation analysis to evaluate the role of
inflammation (C-reactive protein and interleukin-6) in the association between
medications (e.g., antibiotics, PPIs, antipsychotics) and subsequent cognitive
decline.
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Hypothesis: C-reactive protein (CRP), a marker for systemic
inflammation, will mediate the pathway between taking medications associated
with dysbiosis and cognitive scores four years later.
Aim 3. Examine if dysbiosis-related medications (e.g., antibiotics, PPIs,
antipsychotics) are associated with a greater risk of dementia for participants that
were cognitively normal and had MCI at baseline.
Hypothesis: Individuals that are cognitively normal and have MCI at
baseline and are using dysbiosis-related medications will be more likely to be
categorized as having dementia over a 12-year follow-up compared to individuals
not using those medications.
1.2 IMPORTANCE OF RESEARCH
Alzheimer’s disease and related dementias (ADRD), 21 are the sixth
leading cause of death in the United States (US) and fifth among those 65 and
older.22 In 2014, at least 5 million adults ≥65 years had ADRD, which is expected
to almost triple by 2060 to an estimated 13.9 million cases. 3 As the rates of
ADRD increase, the concomitant economic impact related to the care of these
individuals is set to increase. Researchers still do not fully understand the
underlying etiology of ADRD. Various disorders and factors contribute to ADRD,
resulting in a progressive and irreversible loss of neurons and brain functions. 23
Currently, there are no cures for these major neurocognitive disorders. With
limited clinical treatment strategies and cures for ADRD pathology, researchers
have begun to focus on preventive strategies and identifying modifiable
behavioral factors, including regular physical activity, management of
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cardiovascular risk, healthy diet, social connectiveness, and lifelong learning. 24
These same risk reduction principles can be applied to other forms of major
neurocognitive disorders, such as frontotemporal lobar degeneration, Parkinson’s
disease, vascular dementia, and dementia with Lewy bodies. 24
Individuals with mild cognitive impairment (MCI) may transition to ADRD.
One study examining 16 different diagnostic criteria for cognitive impairment
found that between 0.3% to 29% of individuals transitioned to ADRD over a twoyear period.25 This study also found diagnostic criteria that included memory and
non-memory domains resulted in the greatest risk of transition to ADRD.
Predictors of transition from MCI to ADRD include pre-diabetes and diabetes,
metabolic syndrome, neuropsychiatric symptoms, and low dietary folate. 26 One
area of growing research interest is the impact that microbiome disruption may
have on cognitive decline and the development of ADRD.27–31
Evidence suggests that disruption of the microbiome may contribute to
ADRD incidence and progression.32–34 The human body contains trillions of
microorganisms6 known as the microbiota. In an individual with normal
microbiota, microbes that live in the digestive tract perform vital functions of
human health such as energy extraction, protection against pathogen
overgrowth, synthesis of vitamins including folate, and influence on the immune
system.7,35 Disruptions of this healthy gut microflora, known as dysbiosis, can
have negative health impacts. Dysbiosis has been found to be associated with
obesity, allergies, asthma, and Crohn’s disease.10 Recently, the relationship of
the microbiota and major neurocognitive disorders, such as Parkinson’s11 and
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ADRD,12 have also been studied. Individuals that have been diagnosed with
ADRD have been shown to have an altered microbiome, compared to healthy
controls.12,32 Further, evidence suggests that metabolic microbiome profiles of
individuals with MCI who develop ADRD differ from those who do not develop
ADRD.32
Recent evidence suggests medications are associated with changes in the
gut microbiome, with some of the most impactful medications on the microbiome
include PPIs, antibiotics, and second-generation antipsychotics. Antibiotic use is
one of the most common and well established causes of dysbiosis. 8,36,37 Recent
studies found and association between PPIs and a change in a large amount of
microbial taxa and pathways.9 Antipsychotics medications have been found to be
associated with associated with increasing bacteria are related to inflammation
and obesity.19
Dysbiosis caused by medications may lead to cognitive decline and ADRD
through several pathways. Dysbiosis can cause a phenomenon called “leaky
gut,” where disruption of the normal gut flora allows bacteria from the gut to enter
the bloodstream.13 Additionally, the blood brain-barrier becomes more permeable
due to dysbiosis, allowing bacteria from the gut to enter the brain and
compromise health.13 Bacteria in the brain can: 1) increase inflammation in the
brain, which has been associated with ADRD;15,38 and 2) may promote formation
of Aβ through molecular mimicry, a hallmark of AD pathology.17,39 These potential
mechanisms are supported by evidence from numerous studies, including animal
models and observational data.40 41 42,43 36,44–46 Furthermore, the gut microbiota is
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responsible for modulating gut immune, neural, and neuroendocrine pathways;
dysregulation of these functions through dysbiosis is associated with ADRD.33
Disruption of the microbiome, also known as dysbiosis, may have
profound impacts on health and well-being. Evidence suggests that dysbiosis,
and associated markers such as medications (e.g., antibiotics, PPIs,
antipsychotics), may also be related to accelerated cognitive decline and
development of ADRD.47–50 While potential mechanisms to explain this
association have been proposed, there is limited empirical, longitudinal evidence
regarding the strength of this association or its potential mechanisms, such as
inflammation.51
The proposed study has at least three key innovations. First, previous
studies have primarily examined only the associations between dysbiosis,
cognitive function and ADRD in humans cross-sectionally or with short followup;27–30,52 although these studies findings demonstrate an association, lack of
adequate follow-up can potentially undermine their findings through biases and
the rigor of study design. The longitudinal design of the current study allows us to
assess these associations over a period of 12 years where other studies were
limited to one time point or only a few months. Second, this study will be among
the first to examine the association between medications and their interaction
and multiple cognitive outcomes, including changes in global cognition, incidence
of ADRD, and the transition from MCI to ADRD. By combining the datasets, this
study can take advantage of the size and the accuracy of the exposure
information. These findings will therefore have implications for both public health
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and clinical strategies to prevent ADRD. Third, this study uses causal mediation
analysis, an innovative method for isolating causal effects and for understanding
the relative strength of potential mechanisms. This method will allow us to
examine the specific hypothesized role of inflammation in the association of
medications, cognitive decline and ADRD. This project will fill expand the
literature regarding the potential association between medications associated
with dysbiosis and MCI/ADRD. In identifying and quantifying the influence of a
potential risk factor for MCI/ADRD, this project will inform future efforts to delay
and prevent MCI/ADRD.
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CHAPTER 2
LITERATURE REVIEW
The goal of this literature review was to: 1) provide a brief overview of
important concepts and definitions related to studying the influence microbiome
disruption has on mild cognitive impairment (MCI) and Alzheimer’s disease and
related dementias (ADRD) and generally on cognition; 2) define and describe the
dissertation outcomes of interest: MCI and ADRD; and 3) describe what is
currently known about how the disruption of the microbiome influence may have
on dissertation outcomes.
2.1 SEARCH TERMS
A comprehensive literature review was conducted to aid in defining and
describing the influence of exposure (medications associated with dysbiosis) on
the outcomes of interest (MCI and ADRD). The following databases were used:
Pubmed, Psycinfo, and Web of Science. Cited references and studies published
only in English were included. There were no limits set for publication date,
although more recent articles (e.g., published within the past five years) were
favored. The following search terms were used to locate studies evaluating the
association between medications associated with the microbiome, cognitive
impairment, and ADRD: ("Neurocognitive Disorders"[Mesh] OR Alzheimer*[tw]
OR dement*[tw] OR frontotemporal lobar degeneration*[tw] OR “FTD”[tw] OR
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“FTLD”[tw] OR lewy bod* [tw] OR “AIDS dementia”[tw] OR “HIV dementia” [tw]
OR “HIV associated dementia”[tw] OR “ADRD” [tw] OR “HIV associated
neurocognitive disorder*”[tw] OR “Mild cognitive impairment” [tw] OR “Cognition”
[tw] OR “Cognitive impairment” [tw] OR “MCI” [tw] OR “Cognitive decline” [TW])
AND ("Microbiota"[Mesh] OR "Feces/microbiology"[MeSH Terms] OR
"Metabolomics"[Mesh] OR “Microbiome” [tw] OR “Microbiota” [tw] OR
“Metabolomics” [tw] OR “Metabolome” [tw] OR “Gut microbiota” [tw] OR “Gut
microbiome” OR “Microbiome biomarker” [tw] OR “Microbiota biomarker” [tw] OR
“Microbial metabolites” [tw] OR “Fecal microbiota” [tw])
2.2 OUTCOMES
COGNITION
Cognition can have various definitions but can generally be defined as any
form of information processing, mental operation, or intellectual activity such as
thinking, reasoning, remembering, imagining, or learning. 53 Thus, cognition is
used as a global term to describe many different processes the brain uses. To
decompose the different cognitive abelites of the brain, it is best to categorize
them into domains related to specific function. For the purpose of this
dissertation, a few of the most well-established cognitive domains will defined
and used in relation to mild cognitive impairment (MCI) and dementia,
superficially: memory, executive function, and attention. MCI is defined deficits in
memory that do not significantly impact daily functioning while dementia impacts
cognitive skills and the ability to live independently are affected. Both can cause
dysfunction in any of the cognitive domains.
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Memory may be the first thought people have when thinking of cognition.
Memory itself has subdomains. Generally, memory can be defined as the ability
to encode, store, and retrieve information.54 Researchers have found that
memory includes three important subdomains: sensory, short-term, and longterm. Each of these kinds of memory have different attributes, for example,
sensory memory is not consciously controlled, short-term memory can only hold
limited information, and long-term memory can store an indefinite amount of
information. Within long-term memory, there exists semantic and episodic
memory, both with different functions. Semantic memory is related to actual and
conceptual knowledge about the world and the way it expressed in terms of
words, while episodic memory is related to life events that the person has
experienced throughout the phases of his life.55 Memory is typically one of the
first recognizable signs related to cognitive decline, MCI and dementia.56
Attention is another term commonly used in everyday language. In the research
literature, attention is often divided into three main subdomains: selective,
sustained, and divided attention.57 Executive function is a complex cognitive
domain that can be expressed as the ability to plan, initiate, monitor, and carry
out goal-directed behavior.57
COGNITIVE IMPAIRMENT NOT DEMENTIA AND ALZHEIMER’S DISEASE
AND RELATED DEMENTIAS
Mild cognitive impairment (MCI) is defined as mild cognitive or functional
impairment, reported by the participant or informant, or impaired test
performance on the neuropsychological measures that does not reach the
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severity of dementia.58 MCI is estimated to affect 15-20 percent of older adults in
the US.1,59–61 MCI can be a precursor of Alzheimer’s disease and related
dementias (ADRD),62,63 with over 30 percent of individuals diagnosed with MCI
progressing to dementia within five years.1 Although individuals that are
diagnosed or present signs of MCI are at a high risk of transitioning to ADRD,
individuals may remain at MCI or revert back to cognitively normal.64 ADRD are
progressive neurodegenerative disorders affecting individuals’ brain function,
memory, and activities of daily living. There are over hundreds of types of ADRD,
many of which have different pathophysiology’s; however, the most common
ADRD is Alzheimer’s disease, which accounts for 60-70% of all cases.65,66 The
other major forms included vascular dementia, dementia with Lewy bodies, and
frontotemporal dementia.1 ADRD can typically be categorized into two group,
cortical dementias happen because of problems in the cerebral cortex, the outer
layer of the brain (e.g., Alzheimer’s and frontotemporal) and subcortical
dementias happen because of problems in the parts of the brain beneath the
cortex (e.g., vascular dementia and Huntington’s disease). 67
The prevalence of ADRD is expected to triple in the next 40 years leading
to an estimated 14 million people with dementia by 2060. 3 Furthermore, ADRD
affects both the individual and caregiver, as well as the healthcare system. The
Alzheimer’s Association estimated the US’ total direct medical expenditures
related to Alzheimer’s disease-related dementias (ADRD) will increase from $236
billion in 2016 to over $1 trillion in 2050, which does not include the estimated
$221.3 billion for informal caregiving and indirect costs in 2016. 4 There still
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remains no current effective medication or treatment to cure ADRD. However, by
delaying ADRD onset by about five years through identification of high-risk
individuals and early detection and intervention, there is a potential to reduce
both the prevalence and costs of ADRD by 40%.5
Although there are various types of MCI and ADRD, they still share similar
risk factors associated with them. These risk factors can be broken down into
modifiable/preventable and nonmodifiable. The nonmodifiable risk factors
associated with MCI and ADRD are demographics, while the modifiable and
preventable factors are lifestyle and health conditions. The strongest risk factor,
that happens to be nonmodifiable, is age. Gender, race, and family
history/genetics are other nonmodifiable risk factors that are associated with MCI
and ADRD.68 Modifiable risk and preventable factors found to be associated with
MCI and ADRD are lifestyle factors – smoking, exercise, and diet – health
conditions – heart disease, type 2 diabetes, obesity, inflammation, and high
cholesterol levels – and education.69 One recent modifiable factor of interest
related to MCI and ADRD is the gut microbiome.
2.3 EXPOSURES
MICROBIOME
Microbiome is an overarching term to describe the microorganisms (e.g.,
bacteria, fungus, and viruses), their genome, and the symbiotic relationship with
the human body, that live in or on all vertebrates; additionally, the microbiota is
referred to just to the population of microorganisms. The microbiome can
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cohabitate humans’ skin, oral cavity, respiratory tract, and gastrointestinal (gut)
tract.70 The gut microbiome is comprised of the collective genome of microbes
inhabiting the gut including bacteria, archaea, viruses, and fungi and is
composed of bacteria from different phyla 71,72 The gut microbiome has 10 times
the bacterial cells as the host’s cells, with the genes of the gut microbiome
outnumbering the hosts by a 100 to 1;72 however, there is mixed research, as
another study has suggested the ratio may be close to a one-to-one ratio.73 The
extra genes from the microbiome have added various types of enzymatic
proteins that are not produced by the host, and play a critical role in facilitating
host metabolism, thus contributing to the regulation of host heath and
physiology.74
Although not well understood, recent studies found that the gut
microbiome may start to develop and influence health and development from the
fetal environment and continues to develop immediately at delivery and in the
infants’ early life.75–77 In early stages of development, the microbiota is generally
low in diversity and is dominated by two main phyla, Actinobacteria and
Proteobacteria [24,31]. During the first year of life, the diversity of the microbiota
increases, and the microbiota shifts to a similar composition of an adults [32]. By
around two to five years of age, the composition, diversity and functional
capabilities of the infant microbiota resemble those of adult microbiota.78
The microbiome shows a large variability of inter- and intrapersonal
diversify, even in the absence of disease .79,80 This variation is even present in
different geographical regions.78,81 Due to this wide variety in individual profiles, it
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is difficult to establish a definition or a “healthy” microbiome, which is defined as
the absence of any overt disease.82 However, large scale studies were able to
demonstrate consistencies with regards to two bacterial phyla, Bacteroidetes and
Firmicutb es; though, the ratios of these bacteria still vary by individual. 79,80
Analysis of fecal matter through molecular techniques have allowed researchers
to find at least eight bacteria families that are believed to reside in the gut
microbiome: Bacteroides, Clostridium, Prevotellaceae, Eubacteriaceae,
Ruminococcaceae, Bifidodavteriaceae, Lactobacillaceae, Enterobacteriaceae,
Saacharomycetaceeae, Methanobacteriaceae.70 However, since there is vast
diversity among healthy individuals, the notion of a “healthy” microbiome is
difficulty to establish.83 Instead, the large interpersonal differences suggest the
existence of a set of metagomes that are common to individuals. 84,85 Through
this discover, the model of a “core microbiome” was suggested and defined as
the function of the microbiome and not specific to the taxa. 84,85
When the microbiome does experience an altered composition, it is
referred to as dysbiosis or microbiome disruption; however, dysbiotic patterns are
context and disease specific and often not consistently detected among different
studies. Gut dysbiosis is when there are large shifts in the ratio of phyla or the
introduction of new bacteria and may be caused by medications (e.g. antibiotics,
PPIs, antipsychotics), stress, diet, or other factors 8. Research has found a large
number of diseases that are associated with gut dysbiosis, which include:
inflammatory bowel disease,86 metabolic disease,87 and neurological disorders.88
Dysbiosis can occur at any stage of life, with disease-associated dysbiosis being
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shown within an infant in the first few weeks with necrotizing enterocolitis, 88 in
adults with diabetes,89 and older adults with Clostridium difficile (C.
difficile)infection and dementia.39,49,90
Although, in adulthood, the composition of the gut microbiota is relatively
stable, it can change [33]. In individuals over the age of 65, the microbial
community shifts are more normal, with an increased abundance of
Bacteroidetes phyla and Clostridium cluster IV, in contrast with younger subjects
where cluster XIVa is more prevalent [34]. This imbalance in a specific genius of
Clostridium, C. difficile, can cause a disease called C. difficile infection, which is
more prevalent in older adults.90
MEDICATIONS
Over the past decade there has been an increasing interest in the gut
microbiome and factors that alter the ecosystem. Recent research has identified
certain medications that influence the gut microbiome environment. For example,
a study by Vich Vila and colleagues (2020) discovered 19 out of 41 commonly
used medications were associated with microbial features; specifically, PPIs,
metformin, antibiotics, and laxatives showed to influence microbial features the
most.9 A review of non-antibiotic medications and the interaction with the gut
microbiome included the aforementioned medications but also included
information on statins, antidepressants, and opioids. 91
Proton pump inhibitors (PPIs), which are used to reduce stomach acid
production and treat gastroesophageal reflux disease (GERD), are commonly
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used among older adults, with studies suggesting between 27% to 80% of
community dwelling older adults use PPIs.92,93 While the use of PPIs for medical
conditions (e.g., GERD) is effective and necessary, it is estimated that up to 70%
of PPI prescriptions may not be needed.94 A large population-based study found
that the relative abundance of about 20% of bacterial taxa were altered (either
decreased or increased) compared with non-PPI users.95
Antibiotics, used to control bacterial pathogens, has been known to cause
dysbiosis,8,36,44 with recent studies expanding upon these findings. 9,18 Previous
research has found that antibiotics can affect about 30% of the bacterial
ecosystem in the gut.44 After the antibiotic treatment has stopped, the
microbiome may be capable of returning to a similar state as before the
treatment, but often does not fully recover; in fact, dysbiosis can remain after
long periods of time, from months to even years.

36,44,45

Other common drugs, such as antidepressants and laxatives, have been
shown to change the gut microbiome profile.9,96 For example, antidepressants
reduce richness and increase beta diversity of the gut bacteria, which have been
shown to affect gene networks in the brain.97 Further, laxatives have been shown
to change microbial species and metabolic pathways.9 Research has found that
dysbiosis associated with laxatives have long-term alterations to the gut
microbiome.98

17

2.4 EXPOSURE AND OUTCOMES
Researchers have discovered an association between the gut
microbiome, MCI and ADRD, 32–34 suggesting that the gut microbiome may
modify and influence brain function through a microbiome–gut–brain axis.99
However, the underlying mechanisms are still not fully understood. There are
several proposed mechanisms that suggest the modulation of the microbiome–
gut–brain axis. Disruption of the axis can cause and be related to the neuroinflammatory system,100 bacterial lipopolysaccharide (LPS) (a component of the
outer membrane of bacteria) in the brain has the ability to form the aggerate beta
proteins into plaques (which is the hallmark of Alzheimer’s disease), 101 and the
gut microbiota is responsible for modulating gut immune,

102

neural, 103 and

neuroendocrine pathways; 104 dysregulation of these functions through dysbiosis
is associated with MCI and ADRD.33
Previous studies have identified a major cause of dysbiosis, and the
disruption of the microbiome-gut-brain axis is antibiotic use. One recent study
found MCI was caused by antibiotic-induced gut-microbiome dysbiosis in mice,48
while other studies have found similar results in ADRD.18 Further, other studies
have found the use of other commonly used medications are associated with
dysbiosis (e.g., PPIs and antipsychotics).9,19 As previous mentioned, research
has found that dysbiosis can cause a disruption of the microbiome-gut-brain axis
and a phenomenon called “leaky gut,” where the disruption of the normal gut
flora allows bacteria from the gut to enter the bloodstream.13 Additionally, the
blood-brain-barrier becomes more permeable due to this dysbiosis and allows
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the bacteria from the gut to enter the brain and compromise health.13 These
alteration can cause increased inflammation in the brain, which has been
associated with cognitive decline, MCI and AD; these bacteria help form Aβ,
which is a hallmark of AD.17
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CHAPTER 3
METHODS
3.1 OVERVIEW OF THE STUDY
We propose to conduct a secondary data analysis estimating the
association of medications associated with dysbiosis and cognitive decline as
well as the transition from cognitively normal and MCI to ADRD. To measure
these associations, data from the Health and Retirement Study (HRS) from 2004
to 2016 and Prescription Drug Study (PDS) subset from 2005 will be utilized. The
HRS is an ongoing longitudinal study that started in 1992 and follows
approximately 20,000 people per year in the US aged 50 and over. Every two
years, participants are asked a variety of health-related questions, including
cognitive function measures. Data from the HRS core survey and HRS subsets
(described below) will be merged.
SAMPLE
Health and Retirement Study Core Survey. Data for the proposed
research come from the HRS core survey. The HRS is a prospective, populationbased sample of older adults in the US begun in 1992, sponsored by the National
Institute on Aging (NIA U01AG009740) and conducted by the University of
Michigan. Sample collection is based on a multi-stage probability design of
households meant to produce a nationally-representative sample of adults over
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the age of 50.105 Sample weights are provided to account for the complex
sampling design and to make inferences regarding the general US population.
Respondents are re-interviewed every two years. Sample response rates are
presented in Table 1. Core interviews assessed a range of demographic,
socioeconomic, physical functioning, and mental health variables. Data from
HRS core survey and CMS will be used for Aims 1, 2, and 3.
Table 3.1: Total sample and response rates for Health and Retirement Study
core survey only - 2004 – 2016

Wave
7
Year
# of
respondent
s

Wave
8

Wave
9

Wave
10

Wave
11

2004

2006

2008

2010

2012

20,129

18,469

17,217

22,032

20,554

Wave
12

Wave
13

2014 2016*
18,747

20,912

85.30
88.90
88.40
81.00
89.10
87.10
xxx*
%
%
%
%
%
%
Note: *2016 response rates are not available but there is available data for
our study
Rates

HRS Biomarker Data. Starting in 2006, HRS began conducting enhanced
face-to-face (EFTF) interviews, which consisted of a set of physical performance
tests, anthropometric measurements, blood and saliva samples, and selfadministered questionnaire on psychosocial topics. 106 From 2006-2014,
biomarker information was gathered through blood and saliva samples, which
included information on C-reactive protein (CRP) as a marker of systemic
inflammation. The number of EFTF participants from 2006 was 6,735. The
biomarker data will be used in the completion of Aim 2 of this proposal.
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Prescription Drug Study (PDS). In 2005 the first of a two-wave
supplemental Prescription Drug Study (PDS) was initiated through the mail. HRS
participants were selected during the 2004 wave and included respondents that
turned 65 in 2007 or were covered by Medicare or Medicaid between 2002 and
2004. The supplemental study oversampled for that lacking drug coverage or
were low income. During the first wave, information on prescription drug use,
coverage, and satisfaction prior to the implementation of Medicare Part D, as well
as awareness of the new drug benefit and available subsidies was captured.
Overall, 88.1% (4,684) completed the questionnaire or interview. Data from CMS
will be used in the completion of Aims 1, 2, and 3.
MEASURES
Cognitive function. In the HRS, cognitive function is assessed as a
composite measure of recall, working memory, processing speed, and attention
tasks, with scores ranging from 0 to 27.107 In separate analyses, cognitive
functioning will be considered both as a continuous score and categorical
variable - cognitively normal (score:12-27), MCI (score:7-11), and ADRD (score:
0-6). This categorization schema has been used and validated in previous
studies to define ADRD and MCI in the HRS and is consistent with the ADAMS
data set.107 Table 2 (below) presents unweighted sample numbers and weighted
percentages of cognitively normal, MCI, and ADRD for the HRS sample in 2012
from a previous study. A previous study found these measures are able to
classify about 74-79% of individuals into the three-category diagnosis (cognitively
normal, MCI, and ADRD) provided from the ADAMS neuropsychological exam. 108
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Inflammation. From waves 2006-2014, blood was collected from
consenting HRS participants and analyzed for levels of C-reactive protein (CRP);
High-sensitivity CRP was quantified in plasma using enzyme-linked
immunosorbent assays (Cayman Chemical, Ann Arbor, MI, USA). Intra-assay
coefficients of variation ranged from 1.9% to 7.0%. Intra-assay coefficients of
variation ranged from 3.6% to 4.5%, and inter-assay coefficients of variation
ranged from 5.2% to 7.3%.109 CRP will be used for analysis in Aim 2, and during
each wave the inflammatory markers will be operationalized as a continuous
variable. Further analysis is described below in the section Specific Aim 2. As
described in other studies,110 CRP will additionally be assessed as logtransformed to ensure an approximately linear association. CRP is commonly
used in research to assess the presence and severity of chronic, low-grade
inflammation.111
Medications. Medications will be captured through the first PDS wave in
2005. Through literature review, the medications most associated with dysbiosis
are included. These medications are proton pump inhibitors (PPIs), antibiotics,
antidepressants, antipsychotics, antihistamines, and metformin. Data on
duration, dosage, and adherence was not captured or included in analysis. Each
drug was coded class was coded dichotomized as reported as current users and
not reported as not current user. Additionally, a dose-response measure was
calculated by summing each medication reported.
Potential covariates. Potential covariates to use in model selection were
chosen based on previously published literature. To choose appropriate models,
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an empirical method of change-in-estimate (CIE) will be used to assess each of
the covariates of interest. The CIE method uses a ≥10% CIE of the effect of
exposure between models that do and do not adjust for the potential
confounder.112 Based on the literature, potential covariates will be: sociodemographic variables will include age, race, sex, insurance status, residency
location, and education that will come from the HRS dataset. Health-related
variables, also obtained from the HRS, will include number of chronic health
conditions, BMI, and smoking status.
3.2 SPECIFIC AIM 1
To quantify the association between medications (e.g., antibiotics, PPIs,
antipsychotics) and cognitive decline over time. The completion of this aim will
further expand the literature about the longitudinal association of medications
associated with dysbiosis and cognitive decline. Further identification of
medications associated with dysbiosis as a risk factor for cognitive decline may
have important implications for strategies aimed at preventing or slowing
cognitive decline and ultimately ADRD occurrence among older adults and
inpatient and outpatient policies.
Sample. This aim will use waves 2004 to 2016 from the HRS and 2005
PDS subsample datasets to conduct a longitudinal data analysis of the
association between medications and cognitive decline, while controlling for
potential confounders. A total of 43,478 individuals have been interviewed to date
(i.e., between the 1992 and 2016 waves) as part of the HRS (Table 1), with
approximately 20,000 participants at each wave.

24

Measures. We will use the PDS dataset to determine medications use
among HRS participants in 2005. In separate analyses, we will consider each
medication as a binary variable (current user vs. not current user) and as a doseresponse count variable by examining total number of medications (e.g., 0, 1, 2,
or 3). Cognitive decline will be considered as a continuous variable as described
above (see Measures – cognitive function). In a separate analysis, we will
consider cognitive function as a categorical variable using an established cutoff
score to categorize participants as cognitively normal, MCI, or ADRD over time.
Medication will be used as a time-invariant exposure at baseline (Please refer to
the measures subsection under approach (section D) for more information on the
source of data and how each will be measured for medications and cognitive
decline).
Analysis. The association between the exposure (medications) and
outcome (cognitive decline/impairment) will be assessed using a linear mixed
model (LMM) for continuous outcomes and generalized linear mixed models
(GLMM) for categorical outcomes. Respectively, LMM models the expected
change in estimate for cognitive scores, and GLMM the probabilities of having
some value(s). Medication will be considered as a time-invariant exposure, while
comparing cross-sectional versus longitudinal effects. The mixed model
approach was chosen for two reasons. First, mixed-effects models help to
account for the inter-individual correlation of repeated measures of outcomes
over time. Second, these models help account for missing or incomplete
observations over time using likelihood estimation approaches.
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For LMM and GLMM, we will assess the assumptions of the data for the
respective models, including the type of co-variance structure most appropriate
for the data, and whether inclusion of random intercepts and/or slopes in models
is necessary. Model diagnostics/fit will be determined by examining the Akaike
information criteria (AIC). Additionally, for GLMM, the quadrature methods will
use integrals to assess the approximate number of quadrature points to estimate
the marginal log likelihood. We will assess interaction between the exposure and
time, by including an interaction term in LMM and GLMM. This will allow us to
make inferences regarding differences in cognitive changes over time, comparing
those with and without certain medications.
3.3 SPECIFIC AIM 2
To conduct a causal mediation analysis assessing the direct and indirect
effects of medication on cognitive decline. The relationship between medication
and cognitive decline outlined in Aim 1 will be further examined by determining if
inflammation partially mediates the relationship. Data from the PDS (2005),
Biomarker study (2006), and HRS (2008) will be used for this analysis. Cognitive
measures from HRS will only be assessed in 2008, but information about
confounders will be assessed from 2004 and 2006. Completion of this aim will
provide potentially important insights into both the association between dysbiosis
and cognitive decline and a potential mechanism mediating this association inflammation. By quantifying direct and indirect pathways, this project will provide
potential targets for treatment to mitigate the cognitive effects of medications.
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Analysis. A causal mediation analysis will be performed using the
counterfactual framework described by VanderWeele and Vansteelandt (Figure
1).113 The controlled direct effect (CDE), the natural direct effect (NDE), and the
natural indirect effect (NIE) for a change in the exposure variable from one level
to another will be estimated using a sequence of linear regression models for the
expected value of the mediator (conditional on the exposure and confounders),
and the expected value of the outcome (conditional on the exposure, mediator,
their interaction, and confounders). The CDE will estimate the association
between medication and cognitive decline when adjusting for inflammation, while
the NDE will estimate the same association but setting inflammation at the
“naturally occurring level” (or the mediators reference level) of the mediator when
the exposure is set to the reference level. Lastly, we will estimate the degree to
which the association between medication and cognitive decline is mediated by
inflammation through the NIE, which is estimated by comparing levels of the
mediator in those who have the exposure (see next paragraph for the formulas).
For this analysis, the exposure of medication will be categorized into did not use
vs. one medication used and did not use vs. two or more medications used. The
outcome of cognitive decline will be used as a continuous variable (0-27) for
purposes of the mediation analysis via a linear regression. Further, the mediator
variable of inflammation (CRP) will be used as a continuous. Finally, the
proportion mediated (PM) by inflammation will be calculated by (1) 𝑃𝑀 =
𝐼𝐸
(𝑁𝐼𝐸+𝑁𝐷𝐸)

for mediation through linear regression. Lastly, if necessary, a

sensitivity analysis will be performed to evaluate the potential influence of

27

unmeasured, which will be done by recalculating estimates with no unmeasured
confounding, moderate unmeasured confounding, or a strong unmeasured
confounding.

Figure 3.1 Inflammation as a mediator of the relationship between medications
and cognitive decline

3.4 SPECIFIC AIM 3
To examine if dysbiosis-related medications (e.g., antibiotics, PPIs,
antipsychotics) are associated with a greater risk of dementia for participants that
were cognitively normal and had MCI at baseline. Data from the HRS (20042016) and PDS (2005) will be used for this analysis. Completion of this aim may
help to identify a novel predictor of dementia and improve predictions of which
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older adults that are cognitively normal and live with MCI are at greatest risk of
dementia.
Analysis. As described in the in the sample sections above, participants
will be categorized into cognitively normal, MCI, and dementia at baseline (wave
2004 from the HRS core survey). Individuals who are classified with dementia at
baseline will be removed from the study. Those who are classified as cognitively
normal and MCI will be followed up to through wave 2016, and data from PDS
will be used to assess if medication are associated with greater odds of
dementia. Baseline weighted descriptive statistics will be used calculate
frequencies or percentages and means and standard errors (SE) for categorical
and continuous variables, respectively, for all covariates. A generalized linear
mixed model (GLMM) will be used to assess the association between
medications and dementia. For all GLMMs, model assumptions will be checked,
which includes checking the covariance structure for each model and to see if
random intercepts and/or slopes should be included in the model. Further, an
adaptive quadrature method will used to complete maximum likelihood
estimation, which will assess for best fit. The model with the lowest value of
Akaike information criteria will be used to help guide which final model to include.
Separate models will be performed for those that were cognitively normal and
had MCI at baseline. Both GLMM models will be baseline multinomial models; for
example, GLMM will model not dementia (cognitively normal and MCI) vs
dementia and present the probability of having dementia while using baseline
fixed effects and random intercepts and slopes. Additionally, interaction between
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medication and time will be assessed in all models by including the interaction
term in the model; if the interaction term is not significant, it was removed. A
sensitivity analysis will be done with the E-value.26 The E-value is defined as the
minimum strength of association that would be needed by an unmeasured
confounder to be associated with both the exposure and outcome to cause the
results to become null. The larger the E-value, the larger the unmeasured
confounder needs to be to change the results to a null effect. The smaller the Evalue, the smaller the unmeasured confounder needs to be to change the results
to a null effect. We will perform an additional sensitivity analysis by removing
SSRIs and TCAs, antipsychotics, and both from the grouped medications
variable and then assess the models to understand the change in estimates of
each variable.
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CHAPTER 4
ARE DYSBIOSIS-RELATED MEDICATIONS LONGITUDINALLY
ASSOCIATED WITH COGNITIVE PERFORMANCE?1

____________________________________
1

Resciniti N, McLain A, Merchant A, Friedman D, Lohman M. To be submitted to
Alzheimer’s and Dementia Journal
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4.1 ABSTRACT
Recent research has examined how the microbiome may influence cognitive
outcomes; however, there is a paucity of research regarding how dysbiosisrelated medications (DRM) may be associated with cognitive changes. This study
used data from the Health and Retirement Study and the Prescription Drug Study
subset for adults 51 and older (n=3,898) who were followed up for 12 years.
Cognition was measured on a continuous scale using the HRS global cognitive
measure (range: 0-27), and participants were categorized as having normal
cognitive performance (score: 12-27), mild cognitive impairment (score: 7-11), or
dementia (score: 0-6). Baseline prescriptions used were proton pump inhibitors,
antibiotics, selective serotonin reuptake inhibitors, tricyclic antidepressants,
antipsychotics, antihistamines, and a summed measure; all medication have a
known association with dysbiosis. Linear mixed models (LMM) and generalized
linear mixed models (GLMM) were used for continuous and binary cognitive
outcomes, respectively. All models were adjusted for baseline age, race, gender,
education, number of chronic conditions, body mass index, ever smoked, and
number of alcoholic drinks consumed; the categorical medication measure
antidepressants (Selective Serotonin Reuptake Inhibitors (SSRIs) and tricyclic
antidepressants (TCAs)) and antipsychotics additionally were adjusted for
depressive symptoms. Although average cognitive scores for those taking one
medication were not different from those taking zero medications, the interaction
with time showed cognitive scores for those taking one medication declined more
rapidly over time (β: -0.07; 95% confidence interval (CI): -0.14, -0.01). The mean
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cognitive score was lower for those taking two or more medications compared to
those taking no medications (β: -1.48; 95% CI: -2.70, -0.25); however, those
taking two or more medications showed a similar decline in cognitive scores over
time. GLMM results showed those taking two or more medications compared to
those taking no medications had odds that are 377% larger (odds ratio (OR):
4.77; 95% CI: 2.55, 8.95) of having dementia at 2004 (baseline). The interaction
with time showed decreased odds over time (OR: 0.80; 95% CI 0.71, 0.90).
Those who took two or more medications had odds that are 45% larger (OR:
1.45; 95% CI: 1.05, 2.00) of having mild cognitive impairment. This study
indicated those taking more DRM had a greater cognitive decline and a greater
probability of being cognitively unhealthy. Future research should aim to
understand how medications and their combinations directly impact the gut
microbiome and how these changes may influence cognitive changes over time.
4.2 INTRODUCTION
Dementia is a progressive neurodegenerative disorder affecting
individuals’ brain function, memory, and activities of daily living. 1 Approximately 5
million Americans have Alzheimer’s disease and related dementias (ADRD), 1
while roughly 2.4 million have preclinical ADRD or mild cognitive impairment
(MCI).2 With the older adult population's anticipated growth, the prevalence of
ADRD is expected to triple by 2060,3 translating to increased direct and indirect
costs expected to exceed $1.2 trillion in the US. 4 Identifying potential risk factors
of ADRD can delay or may even reduce cases.24,114 By identifying high-risk
individuals and providing early intervention, the onset of ADRD may be delayed –
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– which can reduce both the prevalence and costs associated with ADRD by
40%.5
One growing research area is the gut microbiome's influence on human
health and development. Disruption of the gut microbiome, a collection of
thousands of species of microorganisms harbored within the human body, 6 is
associated with many diseases, including cognitive decline, MCI, and ADRD. A
healthy gut microbiome performs many functions essential for human health,
such as energy extraction, the breakdown of vitamins, protection against
pathogen overgrowth, and immune system regulation. 7 However, disruptions of
the healthy gut microbiome, also known as dysbiosis, can negatively impact
health. Dysbiosis may be caused by stress, diet, medications (e.g., antibiotics,
proton-pump inhibitors), or other factors. It has also been found to be associated
with obesity, asthma, and Crohn’s disease.8–10 Researchers have also examined
the association between dysbiosis and neurodegenerative diseases, such as
Parkinson’s11 and Alzheimer’s disease (AD);12 however, the gut microbiome's
role in the development and progression of these diseases is still not fully
understood. Previous research has found that dysbiosis can cause a
phenomenon called “leaky gut,” where the disruption of the normal gut flora
allows bacteria from the gut to enter the bloodstream.13 Additionally, the bloodbrain-barrier becomes more permeable due to dysbiosis, allowing bacteria from
the gut to enter the brain and compromise brain health. 13,14 These alterations
can: 1) increase inflammation in the brain, which has been associated with
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cognitive decline, MCI, and ADRD,15,16 and 2) promote formation and
accumulation of beta-amyloid, which is a hallmark of AD.17
Antibiotic use is a well-established risk factor for dysbiosis,8,9,115 but recent
studies have found that other commonly used drugs are associated with altering
the gut microbiome.9,18 For example, a recent study found that proton pump
inhibitors (PPIs), used to reduce stomach acid production, were associated with
a change in a large number of microbial taxa and pathways. 9 Antipsychotic
medications, specifically “second-generation” (e.g., risperidone and aripiprazole),
were also found to be associated with increasing bacteria related to inflammation
and obesity.19 Recent studies in the general population showed many other
medications, including commonly used medications such as PPIs and
antidepressants, were associated with gut microbiome composition changes. 9,20
Despite the known association of various medications with dysbiosis and human
health, it is unclear whether the use of these medications is associated with
cognitive outcomes over time. This study aims to quantitatively assess whether
there is an association between medications (e.g., antibiotics, PPIs,
antipsychotics, antihistamines, antidepressants) and cognitive performance over
time. We hypothesize that individuals DRM will experience a greater decrease in
cognitive scores and will be more likely to be categorized as MCI or dementia
over a 12-year follow up compared to individuals not using those medications.
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4.3 METHODS
DATABASE
Data were utilized from the Health and Retirement Study (HRS), a
biennial, ongoing, population-based survey of older adults in the United States
that began in 1992 and included adults older than 50. HRS is conducted by the
University of Michigan and sponsored by the National Institute on Aging (NIA
U01AG009740). The sample collection is based on a multi-stage probability
design meant to produce a nationally representative sample.116 To account for
the intricate sampling design and to generalize to the US population, sample
weights are provided by HRS. Every two years, respondents are re-interviewed
and asked questions about their health, cognition, healthcare utilization, and
demographics.116 Additionally, in 2005, the first of a two-wave supplemental
Prescription Drug Study (PDS) was initiated through the mail. The PDS included
HRS participants in the 2004 wave who turned 65 in 2007 and had health
insurance coverage from Medicare or Medicaid between 2002 and 2004. The
PDS oversampled those who were low income or without supplemental
insurance coverage for medications. Information on prescription drug use,
coverage, and satisfaction before implementing Medicare Part D were captured
during the first wave (2005). Overall, 88.1% (4,684) completed the questionnaire
or interview. The present study used data from six HRS waves (2004 to 2016)
and the PDS (2005), accounting for 12 follow-up years. Of 4,684 individuals who
completed the HRS core survey and the supplemental PDS survey, during the
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study period, 786 individuals did not provide any medication information or were
not in wave 2004, giving a baseline analytic sample of 3,898.
OUTCOME VARIABLES
In the HRS, cognitive function is assessed as a global composite
measure, including measures of immediate (0–10 points) and delayed recall (0–
10 points) memory, a serial 7 subtraction (0–5 points) test for working memory,
and backward counting from 20 (0–2 points) to assess attention and processing
speed, with total scores ranging from 0 to 27.107 Higher scores indicate better
cognitive function. In separate analyses, cognitive functioning was considered
both as a continuous score and categorical variable - cognitively normal (score:
12-27), MCI (score: 7-11), and dementia (score: 0-6). This categorization schema
has been used and validated in previous studies to define dementia and MCI in
the HRS.107. A previous study found these measures can correctly classify
approximately 74-79% of individuals into the three-category diagnosis
(cognitively normal, MCI, and dementia) compared to classification using a more
thorough neuropsychological examination.108
EXPOSURE VARIABLE
Medications were captured through the first PDS wave in 2005. Section E
of the survey asked participants to report all currently prescribed medications,
which allowed zero to seventeen responses. Medications included in the
analyses were guided by previous literature and focused on commonly used
medications associated with dysbiosis.9,91 These medications included were
PPIs, antibiotics, antidepressants (Selective Serotonin Reuptake Inhibitors
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(SSRIs) and tricyclic antidepressants (TCAs)), antipsychotics, and
antihistamines. See the Supplementary Table for specific medications. Data on
duration, dosage, and adherence was not captured or included in the analyses;
due to this, each medication was dichotomized as a current user (as of 2005) or
not a current user. Additionally, a summed medication measure was calculated
by summing each medication reported and then categorized as using no
medication, one medication, or two or more medications. Medications were
considered as a time-invariant exposure.
COVARIATE VARIABLES
Potential covariates used in each model were chosen based on previously
published literature. Covariates used in analyses were socio-demographic
variables that included continuous age, race (white, black, and other), gender
(male and female), and education (less than high school, GED, high school,
some college, and college and above). Health-related variables, also obtained
from the HRS, included the number of chronic health conditions (sum of eight
comorbidities), continuous body mass index (BMI), number of depressive
symptoms, and smoking status (ever smoker and never smoker). All covariates
are baseline measures.
DATA ANALYSIS
Weighted descriptive statistics of the baseline sample were calculated with
frequencies or percentages and means and standard errors (SE) for categorical
and continuous variables. The association between the exposure (medications)
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and outcome (cognitive decline, MCI, and dementia) was assessed using a linear
mixed model (LMM) for continuous outcomes and generalized linear mixed
models (GLMM) for categorical outcomes. For LMM and GLMM, we assessed
the data's assumptions for the respective models, including the type of
covariance structure most appropriate for the data and whether the inclusion of
random intercepts and/or slopes in models is necessary (determined by
examining the Akaike information criteria, AIC). Additionally, for the GLMM, an
adaptive quadrature method was used to complete maximum likelihood
estimation. LMM models estimate the expected change in cognitive scores using
baseline fixed effects and random intercept and slopes. All GLMM models are
baseline multinominal models, i.e., GLMM modeled MCI vs cognitively normal
and dementia vs cognitively normal. GLMM has two separate models that
presents the probabilities of having MCI and dementia while using baseline fixed
effects and random intercepts and slopes. We assessed the interaction between
the exposure (e.g., specific medication or the summed medication measure) and
time by including an interaction term in LMM and GLMM models. The potential
confounders for all models were for age, race, gender, education, number of
chronic conditions, body mass index, ever smoked, and number of alcoholic
drinks consumed; depressive symptoms were considered for those using
categorical medication measure and antidepressants (SSRIs, and TCAs). To
select our final models, we used an empirical method of change-in-estimate
(CIE) to assess which covariates were included in final adjusted analyses. The
CIE method uses a ≥10% CIE of the exposure of interest between models that
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do and do not adjust for the potential confounder. 112 To estimate the strength of
unmeasured confounders required to completely explain away the observed
association, we calculated the E-value proposed by Vanderweele for bipolar
disorder and Schizophrenia for antipsychotic use. 117 Statistical analyses were
performed using the SAS (Statistical Analysis System) software version 9.4 (SAS
Institute, Cary, NC, USA). P values less than 0.05 were considered statistically
significant.
4.4 RESULTS
The analytic sample included 3,898 participants at baseline. Weighted
sample characteristics are described in Table 4.1. The mean age of participants
was 70.00 years (SE = 0.17 years), and 57.65% were females. The majority of
participants were white (87.0%), and 23.92% had less than a high school
education. At baseline, the mean cognitive score was 14.62 (SE: 0.09), 17.16%
were classified as having MCI, and 9.32% were classified as having dementia.
Additionally, 28.39% were using at least one medication related to dysbiosis. The
top medications used were PPIs (14.60%), SSRIs (10.39%), and TCAs (2.45%).
COGNITIVE SCORE
Results for the LMM (Table 4.2) show the unadjusted and adjusted
estimates of the association between medications and cognitive scores. After
adjusting for baseline race, gender, education, BMI, smoking status, drinking,
depressive symptoms, and the chronic disease index, the average cognitive
scores for those using one medication were not different from those taking zero
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medications, but the interaction term showed cognitive scores for those using
one medication had a 0.07 greater decrease (β: -0.07; 95% confidence interval
(CI): -0.14, -0.01), every two years, compared to those using zero medications.
The mean cognitive score was lower for those using two or more medications
compared to those using no medications (β: -1.48; 95% CI: -2.70, -0.25);
however, the interaction term was insignificant and showed those using two or
more medications had a similar decline in cognitive scores over time. However,
we found that average cognitive scores were significantly lower among those
using certain medications. Using antipsychotics showed the strongest
association with lower average cognitive scores (β: -2.82; 95% CI: -4.19, -1.44),
followed by SSRIs (β: -0.92; 95% CI: -1.33, -0.51) and antihistamines (β: -0.90;
95% CI: -1.66, -0.14) users; however, using antibiotics, PPIs, and TCAs were not
associated with cognitive scores. The E-value for the association between
antipsychotic use and MCI was 12.5, with a lower bound of 7.82 and an upper
bound of 17.18, which indicates that an unmeasured confounder required a
strong association with antipsychotic use and MCI by a β of 12.5 each to explain
away the observed association.
MILD COGNITIVE IMPAIRMENT
Table 4.3 shows the unadjusted and adjusted results of the GLMM with
random intercepts and slopes between using medications on MCI or dementia.
We found evidence that using one medication was not significantly associated
with the odds of having prevalent MC at baseline; however, the interaction with
time was insignificant for using one, two or more, and all specific medications
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and was removed from analyses, showing those using any medication had
similar cognitive changes over time. Additionally, using antipsychotics showed
the strongest association (OR: 2.61; 95% CI: 1.38, 4.92) with having MCI, then
by SSRIs users (OR: 1.53; 95% CI: 1.21, 1.94); however, using antihistamines,
antibiotics, PPIs, and TCAs did not show an association. The E-value for the
association between antipsychotic use and MCI was 2.61, with a lower bound of
0.98 and an upper bound of 4.24, which indicates that an unmeasured
confounder required a strong association with antipsychotic use and MCI by an
OR of 2.61-fold each to explain away the observed association.
DEMENTIA
After adjusting and including a group by time interaction (Table 4.3), using
one medication compared to no medications did not have a significant
association with prevalent dementia or interaction with time at baseline. Evidence
suggested that taking two or more medications compared to not taking any
medications was associated with 4.77 (OR: 4.77; 95% CI: 2.55, 8.95) greater
odds of prevalent dementia at wave 2004 (baseline). The estimate representing
the interaction between two or more medications and time suggested that those
taking two or more medications decreasing odds (OR: 0.80; 95% CI: 0.71, 0.90)
of having dementia every two years, after adjusting, compared to those taking no
medications. After expanding the interaction results, we found that years 2006
(OR: 3.81; 95% CI: 2.13, 6.79), 2008 (OR: 3.03; 95% CI: 1.75, 5.27), 2010 (OR:
2.42; 95% CI: 1.40, 4.18), and 2012 (OR: 1.93; 95% CI: 1.09, 3.40) had
significant associations, but 2014 (OR: 1.54; 95% CI: 0.83, 2.83) and 2016 (OR:
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1.22; 95% CI: 0.62, 2.40) did not (Table 4.4). After adjusting and not including
interaction by time, using antipsychotics showed the largest association (OR:
25.48; 95% CI: 10.71, 60.65) with being cognitively normal versus dementia
while using SSRIs was the only other significant medication (OR: 1.49; 95% CI:
1.40, 2.89). The E-value for the association between antipsychotic use and
dementia was 50.45, with a lower bound of 29.54 and an upper bound of 71.36,
which indicates that an unmeasured confounder required a strong association
with antipsychotic use and dementia by an OR of 50.45-fold each to explain
away the observed association.
4.5 DISCUSSION
In a nationally representative cohort of adults aged 51 and older, we found
that the use of SSRIs, antipsychotics, and antihistamines was associated with
greater cognitive decline over 12 years. Participants using SSRIs and
antipsychotics were more likely to have MCI and dementia. Additionally, using
multiple medications appears to be associated with cognitive outcomes.
Cognition among those that used only one medication differs from those who did
not use any of the studied medications. We additionally found evidence that
taking two or more medications had greater odds of dementia at wave 2004
(baseline); although, these odds decreased over time compared to those not
taking dysbiosis-related medications. Further, after expanding the interaction
results, we found that years 2006 to 2012 showed those taking two or more
medications were significantly associated with dementia. This study is one of the
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first to demonstrate an association among those using multiple DRM and
cognitive outcomes.
Previous research has shown that polypharmacy, or taking multiple
medications, is consistently associated with cognitive decline, MCI, and
dementia,118,119 similar to our findings. Our finding of using multiple medications
being associated with the cognitive outcomes is consistent with a recent metaanalysis by Leelakano & D’Cunha (2019).118 They found polypharmacy increased
the risk (relative risk:1.30; 95% CI: 1.16–1.46) of dementia among individuals
>65.118 However, conflicting results have been reported on the association
between specific prescription medications and cognitive decline, MCI, and
dementia.120–125 These contradictory results showed protective, risk, and null
association and could be due to different study designs, definitions, populations,
follow-up lengths, and statistical analyses. For example, studies of the
association between antidepressants and cognitive performance have found
inconsistent results, which could be attributed to inconsistent definition and
medication extraction methods.121,122 One study extracted data from a pharmacy
system that tracks all medication claims and incorporated medication dosages, 121
while another study used self-reported medications and excluded dosages.122
Our research found that using SRRIs, but not TCAs, were associated with
cognitive performance. This is similar to the finding by Then et al. (2017), which
reported significant results for SSRIs (HR: 4.73; 95% CI: 2.54–8.80), and by
Heath and Colleagues (2018), which reported null results for TCAs. 120,121 Studies
have also found PPIs are associated with dysbiosis and cognitive outcomes, 20,123
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but our study showed null results for every cognitive outcome, consistent with a
recent meta-analysis and study.124,125 One explanation of these differences is
both the meta-analysis and our study incorporated a longitudinal design with
random effects,124 showing a null association with dementia. In contrast, a casecontrol 126 and cross-sectional 127 studies showed protective effects.
In our study, using SSRIs, antihistamines, antipsychotics, and multiple
medications were all associated with cognitive changes. Some studies have
reached comparable conclusions regarding the association between specific and
multiple medications with cognitive outcomes. For instance, a recent study using
multiple medications found 1.75-fold increased odds of MCI and 2.33-fold odds of
dementia in a nationally representative cohort.128 Although this study had similar
findings, there are some notable differences. Our study used four self-reported
medications that are associated with dysbiosis and classified as using none, one,
or two or more, while this other study used all self-reported medications and
dichotomized as using zero to four or five or more. Regardless, our study
supports these findings. Further, SSRIs were found to have a faster cognitive
decline129 and increased risk of MCI and dementia in multiple population and
study designs;120 antihistamines have been shown to increase cognitive decline
in a randomized clinical trial;130 and antipsychotics are associated with worsening
cognitive outcomes.131,132 Through multiple populations, study designs, and
follow-up periods, we experienced similar results as previous studies.
There are many reasons why using medications may be associated with
cognitive changes. Research has suggested using specific and multiple
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medications are associated with dysbiosis9,96 and cognitive changes.118,120,132,133
Specifically, in vitro and in vivo studies have demonstrated that antipsychotics,
antihistamines, and antidepressants had substantial effects on the
microbiome20,96,134 and another study showed using multiple medications is
associated with dysbiosis and bacteria species changes among older adults. 134
Further, cognitive changes through dysbiosis is related to a disruption of the
microbiome-gut-brain axis.99 Disruption of this axis can cause systemic
inflammation and increased inflammation in the brain, which has been associated
with cognitive decline, MCI, and dementia15,16 and the ability to aggerate beta
proteins into plaques, which is associated with AD.17,101 Although our study did
not directly measure dysbiosis, inflammation, or beta-amyloid formation; previous
research has demonstrated these associations. Our findings help to support
these potential mechanisms.
This study has several noteworthy strengths. Our study used a nationally
representative sample of older adults, at least 51, with survey weights, which
allowed for generalizability. The PDS medication data, although self-reported,
collects detailed information on medications used, which allows for better
classification of medications. Further, HRS allows for long-term follow-up with
imputed cognitive scores to help with missing data.
There are several potential limitations to our study. First, medication
dosage and duration were not available for analysis which limited categorization
to used and did not use specific medications. Second, the cognitive categories
(cognitively normal, MCI, and ADRD) were not clinical diagnoses; however, these
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categories have been found to correctly classify about 74-79% of individuals
compared to more rigorous clinical neuropsychological battery. 108 Third, there is
potential for informative censoring through loss to follow up due to death. These
individuals may have been more likely to use more medications and have higher
risk of dementia. This may explain the decreasing magnitude of the association
between the using multiple medications and dementia over time. Fourth,
antipsychotics would be prescribed to treat mental illness. If mental illness affects
cognition, then there is the possibility that the association is driven at least in part
by mental illness and not solely the effect of the medications on the microbiome;
however, we conducted a sensitivity analysis to understand how much
unmeasured confounding would be necessary to eliminate the observed
association. Our calculated E-value of 12.5 for the beta-coefficient and 2.61 and
20.52 for MCI and dementia, respectively, showed that an unmeasured
confounding would have to be at this magnitude or greater to explain away our
findings. This seems unlikely, as these E-values are larger than what is found in
the literature.135,136 Lastly, we could not measure individuals' microbiome
diversity to understand how medications directly impact the microbiome. Studies
have found that the medications we included in the analyses were associated
with dysbiosis.9,20,91
In this large nationally representative cohort of older adults, we found that
SSRIs, antihistamines, antipsychotics, and those taking two or more medications
were significantly associated with cognitive outcomes. With the growing aging
population and a substantial proportion of older adults using multiple
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medications, it is vital to understand how medications may interact with the gut
microbiome and how they may influence cognitive changes. Future research
should aim to understand how medications and their combinations directly impact
the gut microbiome and how these changes may influence cognitive changes
over time.
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Table 4.1. Weighted Baseline Demographic and Health Characteristics of the
Analytic Sample
Variable
Baseline (n=3,898)
% (n) or Mean (SE)
Age
70.00 (0.17)
Race
White
87.01% (3,203)
Black
9.03% (546)
Other
3.96% (149)
Gender
Female
57.65% (2,324)
Male
42.35% (1,574)
Education
Less than High-school
GED
High-school
Some college
College and above
Number of chronic
conditions
BMI
Ever smoker

23.92% (1,121)
5.17% (186)
33.20% (1,285)
18.82% (679)
18.89% (626)
2.02 (0.03)
27.54 (0.11)

No
Yes

42.29% (1,588)
57.71% (2,066)

Number of alcoholic
drinks
Number of depressive
symptoms
Antibiotics
Proton Pump Inhibitors
Antidepressants

0.56 (0.02)
1.55 (0.04)
2.23 (90)
14.60% (543)
12.63% (465)
10.39% (376)
2.45% (95)
1.99% (60)
2.17% (94)

SSRI
TCA
Antipsychotics
Antihistamines
Any medication
Zero
One
Two or more

71.61% (2,836)
23.44% (885)
4.95% (177)

Cognitive score at
baseline
Cognitive status at
baseline

14.62 (0.09)

Cognitively normal
Mild cognitive impairment
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73.53% (3,571)
17.16% (746)

Dementia
9.32% (400)
Note: BMI = body mass index; SSRI = selective serotonin reuptake inhibitor; TCA
= tricyclic antidepressant.
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Table 4.2. Unadjusted and Adjusted Linear Mixed Model Results of Medications on Cognitive Scores
Unadjusted β
Adjusted β
Coefficients (95%
Coefficients (95%
Medication
Confidence Interval)
p-value
Confidence Interval)
p-value
Antidepressants
-0.63 (-1.11, -0.15)
0.010
-0.80 (-1.16, -0.42)
<0.001
SSRI
-0.84 (-1.38, -0.31)
0.002
-0.92 (-1.33, -0.51)
<0.001
TCA
0.24 (-0.74, 1.22)
0.637
-0.35 (-1.08, 0.39)
0.359
Antibiotics
0.73 (-0.23, 1.69)
0.137
0.37 (-0.35, 1.08)
0.313
Antihistamines
-1.99 (-2.99, -1.00)
<0.001
-0.90 (-1.66, -0.14)
0.021
Antipsychotics
-3.21 (-4.95, -1.47)
<0.001
-2.82 (-4.19, -1.44)
<0.001
Proton Pump Inhibitors
0.11 (-0.33, 0.54)
0.631
0.04 (-0.29, 0.36)
0.831
Any medication
None
Ref
***
Ref
***
One
0.04 (-0.48, 0.55)
0.891
0.49 (-0.09, 1.07)
0.096
One*time
-0.04 (-0.08, 0.01)
0.113
-0.07 (-0.14, -0.01)
0.029
Two or more
-1.22 (-2.38, -0.05)
0.041
-1.48 (-2.70, -0.25
0.019
Two or
more*time
0.01 (-0.09, 0.11)
0.824
0.02 (-0.12, 0.15)
0.814
Note: SSRI = selective serotonin reuptake inhibitor; TCA = tricyclic antidepressant; All models were adjusted for
age, race, gender, education, number of chronic conditions, body mass index, ever smoked, and number of
alcoholic drinks consumed; Multiple medication measure, antidepressants, SSRIs, and TCAs additionally were
adjusted for depressive symptoms;
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Table 4.3. Unadjusted and Adjusted Generalized Linear Mixed Model Results of Medications on Mild Cognitive
Impairment and Dementia
Mild Cognitive Impairment
Dementia
Unadjusted
Unadjusted
Odds Ratios
Adjusted Odds
Odds Ratios
Adjusted Odds
(95%
pRatios (95%
(95%
pRatios (95%
Confidence
valu
Confidence
pConfidence
valu
Confidence
Medication
Interval)
e
Interval)
value
Interval)
e
Interval)
Antidepressa
1.27 (1.03,
0.02
1.41 (1.14,
0.00
1.65 (1.26,
<0.0
1.70 (1.21,
nts
1.56)
4
1.74)
2
2.16)
01
2.37)
1.34 (1.06,
0.01
1.53 (1.21,
<0.0
1.98 (1.48,
<0.0
1.49 (1.40,
SSRI
1.68)
3
1.94)
01
2.65)
01
2.89)
1.10 (0.74,
0.63
1.14 (0.76,
0.53
0.56 (0.31,
0.06
0.66 (0.34,
TCA
1.62)
5
1.71)
03
1.04)
6
1.29)
0.51 (0.20,
0.15
0.85 (0.55,
0.45
0.54 (0.29,
0.05
0.55 (0.25,
Antibiotics
1.31)
9
1.30)
9
1.01)
4
1.23)
Antihistamine
1.64 (0.96,
0.07
1.36 (0.88,
0.16
1.89 (1.09,
0.02
1.26 (0.65,
s
2.80)
0
2.11)
8
3.27)
4
2.44)
Antipsychotic
1.99 (0.87,
0.10
2.61 (1.38,
0.00
13.28 (6.20,
<0.0 25.48 (10.71,
s
4.55)
5
4.92)
3
28.45)
01
60.65)
Proton Pump
0.99 (0.82,
0.95
0.99 (0.81,
0.91
0.99 (0.76,
0.93
1.02 (0.77,
Inhibitors
1.21)
9
1.22)
8
1.28)
3
1.36)
Any
medication
1.13 (0.96,
0.15
1.07 (0.89,
0.46
***
***
One
1.34)
2
1.29)
9
Two
1.24 (0.90,
0.19
1.45 (1.05,
0.02
or
***
***
1.72)
1
2.00)
5
more
Any

pvalu
e
0.00
2
<0.0
01
0.22
6
0.14
4
0.49
8
<0.0
01
0.89
6

medication
None

Ref

***

Ref

***

Ref
1.46 (1.05,
2.02)
0.99 (0.97,
1.01)

***
0.02
4
0.42
4

Ref
1.52 (0.88,
2.64)
0.98 (0.94,
1.02)

***
0.13
4
0.26
6
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***
***
One
One*ti
***
***
me
Two
4.61 (2.57,
<0.0
4.77 (2.55,
<0.0
or
***
***
8.26)
01
8.95)
01
more
Two
or
0.94 (0.90,
0.00
0.80 (0.71,
<0.0
***
***
more*
0.97)
1
0.90)
01
time
Note: SSRI = selective serotonin reuptake inhibitor; TCA = tricyclic antidepressant; All models were adjusted for age,
race, gender, education, number of chronic conditions, body mass index, ever smoked, and number of alcoholic drinks
consumed; Multiple medication measure, antidepressants, SSRIs, and TCAs additionally were adjusted for depressive
symptoms

Table 4.4. Adjusted Generalized Linear Mixed Model Results of
Taking Two or More Medications' Association with Dementia at Each
Year
Adjusted Odds
Ratios

95% Confidence
Interval

p-value

2004
(Baseline)

4.77

2.55 – 8.95

<0.001

2006

3.81

2.13 – 6.79

<0.001

2008

3.03

1.75 – 5.27

<0.001

2010

2.42

1.40 – 4.18

0.002

2012

1.93

1.09 – 3.40

0.024

2014

1.54

0.83 – 2.83

0.169

Year

2016
1.22
0.62 – 2.40
0.556
Note: Adjusted for age, race, gender, education, number of chronic
conditions, body mass index, ever smoked, number of alcoholic
drinks consumed, and depressive symptoms
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CHAPTER 5
INFLAMMATION AS A POTENTIAL MEDIATOR OF THE
ASSOCIATION BETWEEN DYSBIOSIS-RELATED MEDICATIONS
AND COGNITIVE SCORES2

____________________________________
2

Resciniti N, Merchant A, McLain A, Friedman D, Lohman M. To be submitted to
the Journal of Alzheimer’s Disease
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5.1 ABSTRACT
Dysbiosis-related medications (DRM) and inflammation have been associated
with cognitive decline; however, the role of inflammation in the association of
medication and cognitive scores is unclear. This study used data from the Health
and Retirement Study and data from the Prescription Drug Study and biomarker
sub-studies (n=1,191) from 2004 through 2008. Cognition was measured on a
continuous scale using the HRS global cognitive measure (range: 0-27).
Prescriptions for proton pump inhibitors, antibiotics, selective serotonin reuptake
inhibitors (SSRIs), tricyclic antidepressants (TCAs), antipsychotics,
antihistamines, and medication groups were used; all these medications have a
known association with dysbiosis. C-reactive protein was used for the
inflammatory marker and was log-transformed to ensure an approximately linear
association. We used causal mediation analysis to test the effects of
inflammation in the association of medication use and cognitive scores. All
models were adjusted for baseline age, race, gender, education, number of
chronic conditions, body mass index, ever smoked, and number of alcoholic
drinks consumed; the grouped medication measure, antipsychotics,
antidepressants, SSRIs, and TCAs were additionally adjusted for depressive
symptoms. Although nonsignificant, participants using SSRIs and antipsychotics
had the worst cognitive scores. Users of both SSRIs (β=-0.85; 95% CI: -2.81,
1.11) and antipsychotics (β=-0.98; 95% CI: -2.94, 0.98) experiencing an average
of almost a point lower cognitive score than non-users. Those taking two or more
medications associated with dysbiosis had more than a half-point (β=-0.59; 95%
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CI: -2.55, 1.37) lower cognitive score compared to those using no medications.
Inflammation non-significantly mediated a proportion of these associations,
mediating 35.39%, 35.71%, and 35,59% of SSRIs, antipsychotics, and two or
medications' total effect on cognitive scores, respectively. This study is among
the first to examine the role of inflammation on the association between DRM
and cognitive scores. Future research on the microbiome and inflammation’s role
on medication use and cognitive decline should aim to expand upon these results
to examine if inflammation is a significant mediator in the association of both
medications use and dysbiosis with cognitive scores.
5.2 INTRODUCTION
The number of people living with mild cognitive impairment (MCI) and
dementia in the United States is approximately 2.5 and 5 million, respectively. 1
Research suggests changes in the brain related to MCI or dementia start years
or decades before cognitive symptoms appear.137 Once symptoms occur, it may
be too late to prevent these cognitive problems from occurring. 137 Therefore, it is
vital to identify and understand potentially modifiable risk factors. By identifying
these potential risk factors, and through early interventions, dementia may be
delayed or reduced –– which can decrease both the prevalence and costs
associated with dementia by 40%.5
Medication use has been associated with numerous adverse aspects of
physical and mental health, hospitalization, and mortality. 138–140 For example,
anticholinergic medications are associated with greater risk of hospitalizations
and falls in older adults,138 and using multiple medications is associated with
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greater risk of frailty.140 Commonly used medications have also been found to be
a risk factor for gut microbiome disruption (dysbiosis). 9,96 The microbiome is a
collection of thousands of species of microorganisms harbored within the human
body and related to aspects of human health. 6,7 This is particularly relevant for
older adults, who are more likely to use multiple medications. 141 Growing
evidence suggests that using specific medications and groups of such
medications also have an adverse impact on cognitive function. Previous
research has shown that polypharmacy, or taking multiple medications, is
consistently associated with cognitive decline, MCI, and dementia. 20,120,123
Furthermore, selective serotonin reuptake inhibitors (SSRIs) antidepressants,

120

proton pump inhibitors (PPIs), 20,123 and antihistamines130 have been associated
with dysbiosis, MCI, and dementia.9
Inflammation has been recognized as a risk factor for age-related
diseases and disorders, such as frailty and cognitive decline. 142,143 In previous
epidemiological studies, markers of systemic inflammation are associated with
more significant cognitive decline.142,144 In general, inflammation in the brain can
be due to the brain's immune cells being activated and these pro-inflammatory
responses can cause neurodegeneration and cognitive decline. 145 Dysbiosis is
one potential mechanism that could increase inflammation and increase cognitive
decline.15,16 Research has found that dysbiosis can cause a disruption of the
microbiome-gut-brain axis and a phenomenon called leaky gut, where the
disruption of the normal gut flora allows bacteria from the gut to enter the
bloodstream.13 Additionally, the blood-brain barrier becomes more permeable
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due to this dysbiosis and allows the bacteria from the gut to enter the brain and
compromise health.13 These alterations can cause increased inflammation in the
brain, which has been associated with cognitive decline.15,16 Thus, the links
between medications and cognitive decline may be partially explained through
dysbiosis leading to inflammation.146 Despite these known associations of
various medication use with inflammation and cognitive outcomes, it is unclear
whether inflammation may play a role in the association between dysbiosisrelated medications (DRM) and cognitive scores. We conducted a causal
mediation analysis to evaluate the role of inflammation in the association
between medications and subsequent cognitive decline. We hypothesize that Creactive protein (CRP), a marker for systemic inflammation, will mediate the
pathway between taking DRM and cognitive scores four years later.
5.3 METHODS
The Health and Retirement Study (HRS) was used to conduct a
secondary data analysis that used longitudinal data from 2004 to 2008. The HRS
is an ongoing, nationally-representative prospective sample of individuals aged
50 years and older interviewed biannually since 1992. 105 Every two years,
respondents are re-interviewed and asked questions about their health,
cognition, healthcare utilization, and demographics. 116 Beginning in 2005, the
Prescription Drug Study (PDS) was initiated, which is the first of a two-wave
supplemental survey to the HRS. Participants from the 2004 HRS wave who
turned 65 in 2007 and had health insurance coverage from Medicare or Medicaid
between 2002 and 2004 were included in the PDS. Additionally, the
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supplemental survey asked information related to prescription coverage and
medication. Of the 5,314 eligible cases, 4,684 completed or returned their
survey, accounting for an 88.1% response rate.
Additionally, in 2006, HRS began conducting enhanced face-to-face
(EFTF) interviews, consisting of physical performance tests, anthropometric
measurements, blood and saliva samples, and a questionnaire on psychosocial
topics.106 The 2006 biomarker study gathered information through blood and
saliva samples, which included information on C-reactive protein (CRP) as a
marker of systemic inflammation. The number of biomarker participants from
2006 was 6,735. The present study used data from six HRS waves (2004 to
2008), the PDS (2005), and the biomarker study (2006), accounting for four
follow-up years. Of 4,684 individuals who completed the HRS core survey and
the supplemental PDS survey during the study period, 780 individuals did not
provide any medication information or were not included in wave 2004, limiting
the sample to 3,904. Of the 3,904 participants completing HRS and PDS
surveys, 1,191 were randomly selected for and completed biomarker
assessments. These participants represent the final analytic sample used in this
analysis.
MEASURES
OUTCOME
Cognition was measured in 2008 as a global composite score assessing
immediate (0–10 points) and delayed recall (0–10 points) memory, a serial 7
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subtraction (0–5 points) test for working memory, and backward counting from 20
(0–2 points) to assess attention and processing speed, ranging from 0 to 27. 107
This Lang-Weir classification measure has been previously validated,108,147 with
higher scores indicate better cognitive function.
EXPOSURE
The first PDS wave in 2005 was used to capture participant medication
use. Participants were asked to report all currently prescribed medications.
Previously published articles on commonly used DRM were used to guide which
medications to include in analysis.9,91 Based off these previously published
articles, medications that were most influential on the microbiome were chosen.
Medications included in analyses were proton pump inhibitors (PPIs), antibiotics,
antidepressants (SSRIs and tricyclic antidepressants (TCAs)), antipsychotics,
and antihistamines (See the Supplementary Table for specific medications). Data
on duration, dosage, and adherence was not captured or included in the
analyses; due to this, each medication was dichotomized as a current user (as of
2005) or not a current user. Additionally, a cumulative medication measure was
calculated by summing each medication reported and then grouped as using no
medication, one medication, or two or more medications.
MEDIATING VARIABLE
In wave 2006, blood was collected from consenting HRS participants and
analyzed for levels of CRP. High-sensitivity CRP was quantified in plasma using
enzyme-linked immunosorbent assays (Cayman Chemical, Ann Arbor, MI, USA).
Intra-assay coefficients of variation ranged from 1.9% to 7.0%. Intra-assay
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coefficients of variation ranged from 3.6% to 4.5%, and inter-assay coefficients of
variation ranged from 5.2% to 7.3%.109 CRP was operationalized as a continuous
variable. As described in other studies,110 CRP was additionally assessed as logtransformed to ensure an approximately linear association. CRP is commonly
used in research to assess the presence and severity of chronic, low-grade
inflammation.111 To exclude acute inflammation, calculated CRP values were
used to exclude participants with CRP values greater than 10 mg/L.
COVARIATES
Potential covariates used in each model were chosen based on previously
published literature. These potential covariates were socio-demographic
variables that included continuous age, race (categorized as white, black, and
other), gender (male and female), and education (less than high school, GED,
high school, some college, and college and above). Potential health-related
variables included the number of chronic health conditions (sum of eight
comorbidities), continuous body mass index (BMI), number of depressive
symptoms, and smoking status (ever smoker and never smoker). Baseline
cognitive scores were included in all models. To select appropriate covariates,
we also used an empirical change-in-estimate method. The change-in-estimate
method was used to assess a ≥10% change-in-estimate between the exposure
and outcome.112 Each potential covariate was added to a regression model and if
a ≥10% change was found between the estimate of the exposure and outcome
when the covariate was added, the variable was considered a confounder and
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included in the model. If a model did not meet the ≥10% change, it still could be
included in the model if supported by the literature.
ANALYSIS
Descriptive statistics of the baseline sample were calculated with
frequencies or percentages and means and standard errors (SE) for categorical
and continuous variables, respectively. Causal mediation analysis was performed
using the counterfactual framework described by VanderWeele and
Vansteelandt.113 The controlled direct effect (CDE), the natural direct effect
(NDE), and the natural indirect effect (NIE) for a change in the exposure variable
from one level to another were estimated using a sequence of linear regression
models for the expected value of the mediator (conditional on the exposure and
confounders), and the expected value of the outcome (conditional on the
exposure, mediator, their interaction, and confounders). The CDE estimated the
association between medication and cognitive decline when adjusted for
inflammation, while the NDE estimated the same association but set
inflammation at the naturally occurring level (or the mediator's reference level) of
the mediator when the exposure was set to the reference level. Lastly, we
estimated the degree to which the association between medication and cognitive
decline was mediated by inflammation through the NIE, which was estimated by
comparing levels of the mediator in those who were exposed. Finally, the
proportion mediated (PM) by inflammation was calculated by (1) 𝑃𝑀 =

𝐼𝐸
(𝑁𝐼𝐸+𝑁𝐷𝐸)

for mediation through linear regression. Additionally, pure direct and indirect
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effects were calculated. Statistical analyses were performed using the SAS
(Statistical Analysis System) software version 9.4 (SAS Institute, Cary, NC,
USA).
5.4 RESULTS
Table 5.1 displays descriptive statistics for covariates, mediator (CRP at
wave 2006), and cognitive scores (wave 2008). The analytic sample included
1,191 participants. The mean age of participants was 65.67 years (SD = 7.45
years) and 60.71% were females. The majority of participants were white
(84.38%), and 25.52% had less than a high school education. At baseline,
25.61% were using at least one medication associated with dysbiosis. The most
common medications used were proton pump inhibitors (14.44%), SSRIs
(9.99%), and TCAs (2.43%). At wave 2006, average CRP was 1.82 mg/L, while
log-CRP was 0.08. In 2008, The mean cognitive score was 14.39 (SD: 4.53),
19.33% of participants were classified as having MCI, and 7.41% were classified
as having dementia.
MEDIATION MODELS
COGNITIVE SCORES
Table 4.2 presents the mediation analysis results comparing users versus
non-users of specific and grouped medications. Exposure-mediator interaction
was not detected, and results were not presented. There were no significant
results for the TE, NDE, and NIE for any models; however, we did not find
evidence that users of specific and grouped medications had lower cognitive
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scores compared to non-users. Users of at least one antidepressant type (SSRIs
and/or TCAs) had approximately half a point lower cognitive scores (βTE = -0.47;
95% CI: -1.16, 0.22), while users of SSRIs (βTE = -0.85; 95% CI: -2.81, 1.11) and
TCAs (βTE = -0.60; 95% CI: -2.56, 1.36) had even lower cognitive scores
compared to non-users, although these findings were not statistically significant.
We found no evidence that inflammation mediated the association between users
of antidepressants (βNIE = 0.04; 95% CI: -0.02, 0.09), SSRIs (βNIE = -0.30; 95%
CI: -2.26, 1.66), and TCAs (βNIE = -0.21; 95% CI: -2.17, 1.75) and lower cognitive
scores. Antipsychotic users had worse cognitive scores compared to non-users,
with these users experiencing on average one less point (β TE = -0.98; 95% CI: 2.94, 0.98), although this finding was not statistically significant. Inflammation
mediated the association between antipsychotic users and cognitive scores (β NIE
= -0.35; 95% CI: -2.31, 1.61), which was not significant. Users of one medication
had lower cognitive scores (βTE = -0.10; 95% CI: -2.06, 1.86) compared to nonusers; however, those that used two or medications had over half a point lower
cognitive score compared to non-users (βTE = -0.59; 95% CI: -2.55, 1.37). The
indirect effects of inflammation on the association between one medication (β NIE
= -0.04; 95% CI: -2.00, 1.92) and two or more medication (β NIE = 0.21; 95% CI: 2.17, 1.75) were not significant.
5.5 DISCUSSION
This study examined the association between specific and grouped DRM
and cognitive scores. Since inflammation has been implicated as a mechanism
for medication and dysbiosis associated cognitive decline, the current analyses
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examined whether inflammation mediated these associations. Our study did not
provide any statistically significant results. Participants using SSRIs and
antipsychotics had lower cognitive scores on average compared to non-users of
SSRIs and antipsychotics. This study is among the first to examine the role of
inflammation on the association between medications associated with dysbiosis
and cognitive scores.
Previous research has shown that using medications associated with
dysbiosis and inflammation are both significantly associated with greater
cognitive decline;119,122,131,148 however, findings are inconsistent.129,142,149 We did
not find evidence that those using the specified medications had a greater or
lower cognitive decline over the study period. In contrast, previous studies found
that after a 6-year follow-up period, antidepressant users had about a one-point
greater decline in mean cognitive scores compared to non-antidepressant
users.122 Another study found no evidence for an association between
antidepressant use and cognitive decline in multiple cognitive domains over ten
years of follow-up.129 After two years of follow-up, a nationally representative
study found taking multiple medications was associated with a 0.51-point
decrease in cognitive score.119 In contrast, another longitudinal study found a
non-significant decrease in cognitive scores.149 This is similar to the magnitude
and direction of our study, which found taking multiple medications is associated
with a non-significant 0.59 point reduction. Similar inconsistencies have been
demonstrated for the association of inflammation and cognitive decline. A recent
study has found that log-transformed CRP with a 0.05-point reduction in global
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cognitive scores,148 which is similar to the present findings. Although, another
study demonstrated that CRP does not cross-sectionally or longitudinally predict
cognitive decline.142
Our study showed no significant total, direct, or indirect associations
between the specified medications, inflammation, and subsequent cognitive
decline. There could be several reasons why our results were non-significant,
considering previous research that found similar but significant associations. For
example, one study found antidepressant users, specifically SSRIs, had the
greatest decline in cognitive function over five years, compared with those not
taking any antidepressants.150 Although this study had a similar sample size of
1,234 participants, the study was among only Caucasian women and used MiniMental State Examination, which differs from our population and cognitive
measure and could explain the difference in findings. Another study found using
multiple medications significantly decreased cognitive scores by about half a
point over two years.119 This study was performed within a different country and
used medication frequency and dosage, while our study was limited to users and
non-users. Lastly, Renteria et al. found that higher CRP was associated with
worse cognitive scores.151 However, these researchers used a much larger
sample size of about 20,000 participants, had a 12-year follow-up, and used a
linear latent growth curve model to assess two cognitive domains. In contrast,
our study had approximately 1,000 participants and used linear regression to
assess cognitive scores during our final follow-up wave.
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Our study had strengths worth noting. First, our study included a large
sample of community-dwelling US adults, which utilized data from 2004 to 2008.
Second, we used advanced mediation methods to assess total, direct, and
indirect effects. Although our study has strengths, there are some limitations. The
dependence on observational data imposes limits on causal inference. However,
the longitudinal follow-up of the HRS data allows for the exposure to precede
both the mediator and outcome. Additionally, due to the design of the PDS, we
were not able to measures medication dosage and duration, which limited the
categorization of medications to users and non-users. Further, our study did not
account for loss to follow-up, which could lead to selection bias. Lastly, the study
did not measure an individual’s microbiome diversity to understand how
medications directly impact the microbiome; however, studies have found the
included medications were associated with dysbiosis.9,20,91
In conclusion, our study directly tested the mediatory role of inflammation
on the association of using medications associated with dysbiosis and cognitive
scores. Our findings did not find evidence that using any medication was
associated with cognitive scores or that inflammation played a mediating role;
however, the magnitude and direction of our results are similar to what has been
previously observed. The non-significant results suggested that a larger
proportion of the total effect could be mediated through inflammation. Future
research on the microbiome and inflammations role on medication use and
cognitive decline should aim to expand upon these results by collecting
microbiome samples, multiple inflammations measures, and more robust
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medication information to examine if inflammation is a significant mediator in the
association of both medication use and dysbiosis with cognitive scores. By
providing these results, providers can incorporate monitoring of their patients’
microbiome and inflammatory markers to help reduce cognitive decline through
medication selection.
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Table 5.1. 2004 Baseline Demographic and Health Characteristics of the Analytic
Sample
Variable

Baseline (n=1,191)
% (n) or Mean (SD)

Age (years)

65.67 (7.54)

Race
White

84.38% (1,005)

Black

12.68% (151)

Other

2.94% (35)

Gender
Female

60.71% (723)

Male

39.29% (468)

Less than High-school

25.52% (304)

Education

GED

6.05% (72)

High-school

31.32% (373)

Some college

19.65% (234)

College and above

17.46% (208)

Sum of chronic
conditions

1.48 (1.15)

BMI (kg/m2)

27.66 (5.20)

Ever smoker
No

45.45% (494)

Yes

54.55% (593)

Number of alcoholic
drinks per day

0.52 (1.06)
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Number of depressive
symptoms

1.46 (1.84)

Antibiotics

2.27% (27)

Proton Pump Inhibitors

14.44% (172)

Antidepressants

11.92% (142)
SSRI

9.99% (119)

TCA

2.43% (29)

Antipsychotics

1.01% (12)

Antihistamines

1.87% (23)

Any medication
0

74.39% (886)

1

21.66% (258)

2

3.95% (47)

CRP Level (2006)

1.82 (1.93)

Log-CRP Level (2006)

0.08 (1.07)

Cognitive score (2008)

14.39 (4.53)

Cognitive status (2008)
Cognitively normal

73.26% (811)

Cognitive impairment

19.33% (214)

Dementia

7.41% (82)

Note: BMI = body mass index; SSRIs = selective serotonin reuptake inhibitors;
TCAs= tricyclic antidepressants; CRP = C-reactive protein
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Table 5.2. Direct, Indirect, and Total Effects of Medications Associated with Dysbiosis on Cognitive Scores (n =
1,191)
Unadjusted β Estimates

Medication

TE

DE

IE

TE

PM

0.02 (0.06, 0.11)

-0.33 (1.19, 0.53)

-0.51 (1.20, 0.18)

0.04 (-0.02,
0.09)

-0.47 (1.16, 0.22)

8.51%

SSRIs

-0.33 (1.26, 0.60)

0.02 (0.06, 0.10)

-0.31 (1.24, 0.61)

-0.55 (2.51, 1.41)

-0.30 (2.26, 1.66)

-0.85 (2.81, 1.11)

35.29%

TCAs

-0.20 (2.07, 1.68)

0.03 (0.09, 0.15)

-0.17 (2.04, 1.70)

-0.39 (2.35, 1.57)

-0.21 (2.17, 1.75)

-0.60 (2.56, 1.36)

35.00%

Antibiotics

0.96 (-0.84,
2.75)

0.00 (0.02, 0.03)

0.96 (-0.84,
2.75)

-0.05 (2.01, 1.91)

-0.03 (1.99, 1.93)

-0.08 (2.05, 1.88)

37.50%

Antihistamines

0.43 (-1.44,
2.30)

0.01 (0.04, 0.05)

0.44 (-1.43,
2,31)

-0.06 (2.02, 1.90)

-0.03 (1.99, 1.93)

-0.09 (2.05, 1.87)

33.33%

Antipsychotics

-0.06 (3.04, 2.91)

0.01 (0.04, 0.05)

-0.06 (3.03, 2.92)

-0.63 (2.59, 1.33)

-0.35 (2.31, 1.61)

-0.98 (2.94, 0.98)

35.71%

Proton Pump
Inhibitors

0.11 (-0.66,
0.88)

0.00 (0.01, 0.02)

0.11 (-0.66,
0.88)

0.13 (-1.83,
2.09)

0.07 (-1.89,
2.03)

0.20 (-1.76,
2.16)

35.00%

Ref

Ref

Ref

Ref

Ref

Ref

Antidepressants

DE

IE

-0.36 (1.22, 0.51)

Adjusted β Estimates
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Any medication
None

One

0.10 (-0.57,
0.76)

0.01 (0.02, 0.03)

0.10 (-0.57,
0.77)

-0.07 (2.03, 1.89)

-0.04 (2.00, 1.92)

-0.10 (2.06, 1.86)

40.00%

Two or
more

0.02 (-1.45,
1.49)

0.01 (0.10, 0.12)

0.03 (-1.43,
1.50)

-0.38 (2.34, 1.58)

-0.21 (2.17, 1.75)

-0.59 (2.55, 1.37)

35.59%

Note: TE = total effect; DE = direct effect; IE = indirect effect; SSRIs = selective serotonin reuptake inhibitors;
TCAs= tricyclic antidepressants; All models were adjusted for age, race, gender, education, number of chronic
conditions, body mass index, ever smoked, number of alcoholic drinks consumed, and baseline cognitive scores;
Multiple medication measure, antipsychotics, antidepressants, SSRIs, and TCAs additionally were adjusted for
depressive symptoms.
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CHAPTER 6
DIFFERING LONGITUDINAL ASSOCIATIONS BETWEEN DYSBIOSIS
RELATED MEDICATION AND DEMENTIA AMONG COGNITIVELY HEALTHY
AND MILD COGNITIVE IMPAIRMENT AT BASELINE3

____________________________________
3

Resciniti N, McLain A, Merchant A, Friedman D, Lohman M. To be submitted to
Dementia
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6.1 ABSTRACT
Dysbiosis-related medications have been found to be associated with dementia;
however, the association of dysbiosis-related medication and dementia is still not
well understood. This study used data from the Health and Retirement Study and
data from the Prescription Drug Study supplemental study (n=3,594) from 2004
through 2016. Cognition was measured on a continuous scale using the HRS
global cognitive measure (range: 0-27), and participants were categorized as
having normal cognitive performance (score: 12-27), mild cognitive impairment
(MCI; score: 7-11), or dementia (score: 0-6). Those that were categorized with
dementia at baseline (2004) were excluded. We considered self-reported
prescription to medications known to be associated with dysbiosis as the primary
determinant of interest, which included baseline proton pump inhibitors,
antibiotics, Selective Serotonin Reuptake Inhibitors (SSRIs), Tricyclic
Antidepressants (TCAs), antipsychotics, antihistamines. Additionally, all
medications were summed and then grouped into zero, one, and two or more
medications used. All these medications have a known association with
dysbiosis. Generalized linear mixed models were used to estimate odds of
dementia over the study period comparing those with and without medication
use. All models were adjusted for baseline age, race, gender, education, number
of chronic conditions, body mass index, smoking history, and number of alcoholic
drinks consumed; the grouped medication measure, antipsychotics,
antidepressants, SSRIs, and TCAs were additionally adjusted for depressive
symptoms. Individuals taking two or more medications compared to those taking
no medications had 188% (OR: 2.88; 95% CI: 1.08, 7.67) greater odds of being
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categorized as having dementia, while the interaction with time showed 14%
decreased odds (OR: 0.86; 95% CI: 0.80, 0.93) of having dementia every two
years. This study is among the first to examine the association of dysbiosisrelated medications and dementia. Future research on the role of medications in
the microbiome and dementia should aim to understand the biological
mechanisms by which these medications change the microbiome and cognitive
function.
6.2 INTRODUCTION
The number of older adults with Alzheimer’s disease and related dementia
(ADRD) in the United States is expected to triple from approximately 5 million to
15 million by 2060.1 This does not account for an additional 2.4 million individuals
currently living with pre-clinical ADRD or mild cognitive impairment (MCI).1 With
ADRD being a progressive neurodegenerative disorder with no known cure, 1
identifying and understanding potentially modifiable risk factors is vital to delay or
possibly reduce cases. If the development of an ADRD could be delayed by five
years, the prevalence and cost associated with ADRD could be reduced by
approximately 40%.2
With no cure and limited treatment of ADRD, considerable research has
been focused on identifying modifiable and non-modifiable risk factors, such as
age, diabetes, and diet.3,4 A recent research focus has been understanding how
the gut microbiome influences human health and development. The gut
microbiome is a collection of thousands of species of microorganisms.5 A healthy
gut microbiome performs many functions essential for human health- such as
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energy extraction, the breakdown of vitamins, and immune system regulation. 6
Dysbiosis, or a disruption of the gut microbiome, can negatively impact health.7
Stress, diet, and medications (e.g., antibiotics, proton-pump inhibitors) are known
risk factors for dysbiosis,8–10 which can be associated with obesity, asthma, and
Crohn’s disease.8,11,12 Recently, the relationship of the microbiota and major
neurocognitive disorders, such as Parkinson’s13 and ADRD,14 have also been
studied. Individuals that are diagnosed with ADRD have been shown to have an
altered microbiome compared to healthy controls. 14,15 Further, evidence suggests
that metabolic microbiome profiles of individuals with MCI who develop ADRD
differ from those who do not develop ADRD.15 However, we do not fully
understand the gut microbiome's role in the development and progression of
these diseases.
Recent studies have examined the association between medication use
and dysbiosis. The most commonly studied medication groups associated with
dysbiosis has been antibiotics, which can cause dysbiosis for months to
years.11,16,17 Other studies have found that other commonly used drugs are
associated with altering the gut microbiome.8,18 Recent studies in the general
population showed many other medications, including commonly used
medications such as PPIs and antidepressants, were associated with gut
microbiome composition changes.8,19 A study by Vich Vila (2020) identified
proton pump inhibitors (PPIs), which are used to reduce stomach acid
production, were associated with the largest change in composition and function
of the gut microbiome.8 Additionally, a mouse model demonstrated that various
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types of antidepressants alter gut microbiome composition. 20 Despite the known
association of various medications with dysbiosis and human health, it is unclear
whether the use of these medications is associated with cognitive outcomes over
time. This study examined if dysbiosis-related medications (e.g., antibiotics,
PPIs, antipsychotics) was associated with a greater risk of dementia for
participants that were cognitively normal and had MCI at baseline. We
hypothesize that individuals that are cognitively normal and have MCI at baseline
and are using dysbiosis-related medications will be more likely to be categorized
as having dementia over a 12-year follow-up compared to individuals not using
those medications.
6.3 METHODS
DATABASE
Data were from 2004 to 2016 of the Health and Retirement Study (HRS).
Starting in 1991, the HRS surveys older adults aged 51 or older in the United
States every two years. The HRS is funded by National Institute on Aging and
the Social Security Administration and is conducted by the University of
Michigan. Information is collected with a multistage area probability sample of US
households, which is meant to account for a nationally representative sample of
older adults.21 To account for the complex study design, HRS provides sample
weights for analysis. Generally, participants are asked questions regarding
economic, health, cognition, demographics, and healthcare utilizations.21
Beginning in 2005, the HRS initiated the Prescription Drug Study (PDS).
The PDS is a supplemental study of the HRS during 2005 and 2007 that tracked
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changes in prescription drug utilization with a mail survey design. The
supplemental study oversampled those who were low income or without
supplemental insurance coverage for medications. The PDS included individuals
from the 2004 HRS wave who were to turn 65 in 2007 and had health insurance
coverage from Medicare or Medicaid between 2002 and 2004 for the 2005 PDS
sample. Overall, 88.1% (4,684) completed the questionnaire or interview.
The present study used data from seven HRS waves (2004 to 2016) and
the PDS (2005), which accounted for up to 12 follow-up years. Of 4,684
individuals who completed the HRS core survey and the supplemental PDS
survey, 307 were categorized as having dementia, and 813 did not provide any
medication information or were not in wave 2004, giving a baseline analytic
sample of 3,594.
COGNITIVE VARIABLES
The HRS assessed cognitive function as a global composite measure that
included measures of immediate (0–10 points) and delayed (0–10 points) recall
memory, a serial 7 subtraction (0–5 points; to test for working memory), and
backward counting from 20 (0–2 points; to assess attention and processing
speed). The scores ranged from 0 to 27,22 with higher scores indicating better
cognitive function. This study used the categorization of cognitively normal, MCI,
and dementia validated by Langa and Colleagues, 22 which are defined as
cognitively normal (score: 12-27), MCI (score: 7-11), and dementia (score: 0-6).
At baseline (2004), participants that were categorized as having dementia were
excluded from the study. After baseline (2004), the study grouped those
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categorized as cognitively normal and MCI as “not having dementia” and
compared these individuals to those “having dementia”. Compared to a
neuropsychological examination done in a supplemental study of the HRS,
researchers found that these measures could correctly classify approximately 7479% of individuals into the three-category diagnosis (cognitively normal, MCI,
and dementia).23
MEDICATION VARIABLES
In the 2005 wave of the PDS participants were asked about medications
they were currently taking, which allowed zero to seventeen responses.
Previously published articles on commonly used medications associated with
dysbiosis were used to guide which medications to include in the analysis. 8,24 We
chose the most influential medications on the microbiome based on these
previously published articles. Those included were proton pump inhibitors (PPIs),
antibiotics, antidepressants (Selective Serotonin Reuptake Inhibitors (SSRIs) and
tricyclic antidepressants (TCAs)), antipsychotics, and antihistamines. See the
Supplementary Table for specific medications.
Since the PDS did not ask questions on duration, dosage, and adherence,
we could not include this in the analysis. Alternatively, each participant was
dichotomized as a current or not a current user of each specific medication. A
cumulative medication measure was calculated by summing each medication
reported and then grouped in two ways: 1) using no medications and one or
more medications and 2) using no medication, one medication, or two or more
medications. Medications were considered as a time-invariant exposure.
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COVARIATE VARIABLES
Potential covariates used in each model were guided by previously
published literature, and final models were selected in conjunction with an
empirical method of change-in-estimate (CIE) to assess which covariates were
included in final adjusted analyses. This CIE method uses potential covariates in
individual models to see if there is a ≥10% change in estimate; if there is a ≥10%,
the variable is considered a confounder and included in the final model.25
Covariates used in analyses were socio-demographic variables that included
continuous age, race (white, black, and other), gender (male and female), and
education (less than high school, GED, high school, some college, and college
and above) from the HRS dataset. Health-related variables, also obtained from
the HRS, included the number of chronic health conditions (sum of eight
comorbidities), continuous body mass index (BMI), number depressive
symptoms, and smoking status (ever smoker and never smoker). All covariates
are baseline measures.
DATA ANALYSIS
Baseline weighted descriptive statistics were calculated for all covariates
and cognitive status using frequencies or percentages and means and standard
errors (SE) for categorical and continuous variables, respectively. A generalized
linear mixed model (GLMM) was used to assess the association between
medications and dementia. For all GLMMs, model assumptions were checked,
which included assessing if random intercepts and/or slopes should be included
in the model. Further, adaptive quadrature was used to complete maximum
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likelihood estimation. Separate models were performed for those that were
cognitively normal and had MCI at baseline. The potential confounders for all
models were for continuous age, race (white, Black, and other), gender (male
and female), education (less than high school, GED, high school, some college,
college and above), number of chronic conditions (sum of eight conditions),
continuous body mass index (BMI), ever smoked (yes and no), and number of
alcoholic drinks consumed; continuous depressive symptoms were considered
for those using categorical medication measure and antidepressants (SSRIs and
TCAs). Additionally, interaction between medication and time was assessed in all
models by including the interaction term in the model; if the interaction term was
not significant, it was removed. For medications that have a significant interaction
with time, an estimate was calculated for each year to assess if medications were
significantly associated with dementia at each year. A sensitivity analysis was
done with the E-value.26 The E-value is defined as the minimum strength of
association that would be needed by an unmeasured confounder to be
associated with both the exposure and outcome to cause the results to become
null. The larger the E-value, the larger the unmeasured confounder needs to be
to change the results to a null effect. The smaller the E-value, the smaller the
unmeasured confounder needs to be to change the results to a null effect. We
ran an additional sensitivity analysis by removing SSRIs and TCAs,
antipsychotics, and both from the grouped medications variable and then
assessed the models to understand the change in estimates of each variable.
Statistical analyses were performed using the SAS (Statistical Analysis System)
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software version 9.4 (SAS Institute, Cary, NC, USA). P values less than 0.05
were considered statistically significant.
6.4 RESULTS
The analytic sample included 3,594 participants at baseline of which
80.68% (n = 2,805) were cognitively normal and 19.33% (n = 789) had MCI.
Weighted sample characteristics stratified by baseline cognitive status
(cognitively normal and MCI) are described in Table 6.1. The mean age of
participants was significantly lower (p < 0.001) for those that were cognitively
normal (64.69) compared to MCI (68.61). For those that were cognitively normal
at baseline, they tended to report being white (90.71% vs. 77.57%; p < 0.001),
more college experience (23.02% vs. 6.70%; p < 0.001) and lower number of
chronic conditions (1.45 vs. 1.76; p < 0.001) compared those that had MCI. Both
those categorized as being cognitively normal and that had MCI were using PPIs
(14.26 vs. 16.12%; p = 0.294), SSRIs (9.45% vs. 10.19; p = 0.655), and TCAs
(2.55% vs. 2.36%; p = 0.800) the most frequently.
Results indicated that there was no significant association between the
use of only one dysbiosis-related medication and odds of dementia for those that
were cognitively normal (OR: 1.36; 95% CI: 0.82, 2.27) and MCI (OR: 1.09; 95%
CI: 0.63, 1.88) at baseline (Table 6.2). Further, we found no evidence of an
interaction between using one dysbiosis-related medication and time, suggesting
that the change in cognitive scores over time did not differ based on dysbiosisrelated medication use. Those that were cognitively normal results showed no
significant association between the use of two or more dysbiosis-related
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medications and odds of dementia (OR: 2.27; 95% CI: 1.00, 5.64). Further, we
found no evidence of an interaction between two or more dysbiosis-related
medication and time among those that were cognitively normal, suggesting that
the change in cognitive scores over time did not differ based on dysbiosis-related
medication use. However, for those categorized as having MCI at baseline,
evidence suggested that taking two or more medications compared to not taking
any medications was associated with 2.88 (odds ratio (OR): 2.88; 95%
confidence interval (CI): 1.08, 7.67) greater odds of having dementia at wave
2004 (baseline). The estimate representing the interaction between two or more
medications and time suggested that those taking two or more medications had
14% lower odds (OR: 0.86; 95% CI: 0.80, 0.93) of having dementia every two
years, after adjusting, compared to those taking no medications. Although, after
expanding the interaction results, we found that there was no significant
association between taking two or more medications and dementia after baseline
among those who had MCI (Table 6.3). Results indicated that there was no
significant association between the use of one or more dysbiosis-related
medication and odds of dementia for those that were cognitively normal (OR:
1.48; 95% CI: 0.92, 2.37) and MCI (OR: 1.28; 95% CI: 0.76, 2.14) at baseline.
Further, we found no evidence of an interaction between using one or more
dysbiosis-related medication and time, suggesting that the change in cognitive
scores over time did not differ based on dysbiosis-related medication use. No
other medications had a significant interaction with time, and the interaction term
was removed from the respective models. In adjusted models, use of an
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antipsychotic was most strongly associated with greater odds of dementia for
both those that were cognitively normal (OR: 7.41; 95% CI: 2.03, 27.03) and MCI
(OR: 9.28; 95% CI: 2.00, 21.52) at baseline, compared to those who did not use
an antipsychotic. Only among those who had MCI showed those who used
antihistamines compared to those who did not had 83% (OR: 0.17; 95% CI: 0.06,
0.53) lower odds of being categorized as having dementia after adjusting. Those
who used SSRIs, TCAs, PPIs, and antibiotics were not associated with odds of
dementia in both groups.
SENSITIVITY ANALYSIS
The E-value for the association between antipsychotic use and dementia
was 14.30 for cognitively normal and 18.05 for MCI, with a lower bound of 10.82
and14.64 and an upper bound of 17.78 and 21.46, respectively, for those who
were cognitively normal and MCI. This indicated that an unmeasured confounder
required a strong association with both antipsychotic use and dementia by an OR
of 14.30 and 18.05-fold, respectively, for cognitively normal and MCI, each to
cause the association to become null. Further, among those that had MCI, the Evalue for using two or more medications was 5.21 (OR: 5.21; 95% CI: 3.84, 6.58)
and the E-value for the interaction of taking two or more medications and time
was 1.36 (OR: 1.36; 95% CI: 0.24, 2.96). For the estimate of just taking two or
more medications, a strong association with both taking two or more medications
and dementia is needed to change the findings to null. However, the E-value for
the interaction term is smaller, suggesting small unmeasured confounding may
be able to change our inference. Lastly, among those that had MCI, the E-value
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for the association between using an antihistamine was 11.24 (OR: 11.24; 95%
CI: 8.06, 14.42). With the E-value being large, this suggests large unmeasured
confounding is needed to change the results to null.
When removing SSSRIs and TCAs medications from the grouped
medication variable, we found that taking two or more medications compared to
not taking any medications changes from being significant (OR: 2.88; 95%; CI:
1.08, 7.67) to nonsignificant (OR: 2.87; 95%; CI: 0.30, 27.79). Further, the
interaction between two or more medications and time changed from being
significant (OR: 0.86; 95% CI: 0.80, 0.93) to nonsignificant (OR: 0.90; 95% CI:
0.77, 1.04). Removing antipsychotic medications from the grouped medication
variable changed the findings of taking two or more medications compared to not
taking any medications changes from being significant (OR: 2.88; 95%; CI: 1.08,
7.67) to nonsignificant (OR: 2.77; 95%; CI: 0.93, 8.29). However, the interaction
between two or more medications and time remained significant for both the
initial analysis (OR: 0.86; 95% CI: 0.80, 0.93) and sensitivity analysis (OR: 0.86;
95% CI: 0.79, 0.93). After removing SSRIs, TCAs, and antipsychotics, the main
effect of taking two or more medications changed to a nonsignificant decreased
odds of dementia (OR: 0.28; 95%; CI: 0.03, 3.22) and the estimate representing
the interaction between two or more medications and time became nonsignificant
(OR: 0.92; 95% CI: 0.79, 1.08).
6.5 DISCUSSION
This study examined the impact of specific (e.g., antidepressants,
antibiotics, antipsychotics, antihistamines, and PPIs) and grouped (e.g., zero,
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one, and two or more) medications on having dementia among those who were
cognitively normal or had MCI at baseline. In a nationally representative cohort of
older United States adults, we found that the use of antipsychotics among those
who were cognitively normal and had MCI at baseline were associated with
greater odds of dementia but did not find evidence of these odds changing over
time. Additionally, we found that among those who had MCI, individuals who
used antihistamine showed lower odds of dementia compared to non-users but
did not find evidence of these odds changing over time. We additionally found
evidence that those who had MCI and were taking two or more medications had
greater odds of dementia at wave 2004 (baseline); although, these odds
decreased over time compared to those not taking dysbiosis-related medications.
However, after expanding the interaction results, we found that there was no
significant association between taking two or more medications and dementia
after baseline among those who had MCI. This study is one of the first to
demonstrate an association among those using specific and multiple dysbiosisrelated medications and dementia.
Our study demonstrated that taking certain dysbiosis-related medication
was associated with dementia, which is similar to previous findings;27–31 however,
some findings are inconsistent.32,33 Although there are limited studies related to
antipsychotics and dementia, one study found those that used antipsychotics had
2.1 times the risk (HR = 2.1, 95% CI = 1.4 – 3.3) compared to non-users,34 which
is similar to our results. This current study did not find a significant association
between SSRI antidepressants, TCA, or grouped antidepressants and dementia.
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A systematic review and meta-analysis reported a 75% increased risk of
dementia for those taking SSRIs compared to non-SSRI users,35 while another
study found null results for TCA users.32 However, another study found those
taking antidepressants had a reduced rate of dementia.36 One reason these
studies on antidepressant use could provide conflicting results is that the study
providing evidence of increased risk of dementia was a meta-analysis. In
contrast, the study demonstrating a protective effect of antidepressants on the
rate of dementia was a cohort study. A meta-analysis found that PPIs were not
associated with dementia, 37 similar to our findings, but other studies have found
them to be associated.38 Antihistamines have mixed findings on how they are
associated with dementia. One study found a nonsignificant association between
antihistamines and dementia,30 while another study found that antihistamines
reduce risk of dementia,31 which is similar to what our study found. More
consistently, findings related to taking multiple medications and dementia have
been reported.28,39,40 A recent meta-analysis found taking multiple medication
had a 30% (relative risk: 1.30; 95% CI: 1.16 – 1.46) increased risk of dementia.40
Our study identified that antipsychotics among participants who were
cognitively normal and MCI at baseline were associated with dementia. Further,
we found that taking antihistamines and multiple medications was associated
with dementia among those who had MCI. Some studies have reached
comparable conclusions regarding the association between specific and multiple
medications with cognitive outcomes. For example, a recent meta-analysis found
that those taking multiple medications had a 30% increased risk of developing
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dementia compared to those not taking any medications.40 Our point estimate
provided similar results; however, the multiple medications interaction with time
provided evidence that those who take two or more medications had decreasing
odds of being categorized as having dementia over time. Unfortunately, this
meta-analysis and the studies included did not examine interaction with time and
cannot be compared. There are some other notable differences. Our study used
four self-reported medications associated with dysbiosis and classified as using
none, one, or two or more, while this meta-analysis combined studies that used
self-reported medications and medications from a medical record used varying
cutoffs of at least five medications. A study on antihistamine use and the
association with Alzheimer’s disease found that those who use antihistamines
have 58% lower odds of Alzheimer’s,31 which our study found comparable
findings. Although this study used a case-control design and was among only
individuals with Alzheimer’s disease, our study helps to support their conclusions.
Lastly, one study on antipsychotics demonstrated an association with dementia.34
This study had a large sample of about 15,000 participants and a follow-up
period of 12 years; however, the study population was among veterans, which
may help explain differences in our results where their results of 2.1 increased
risk of dementia and ours found 10.18 increased odds of dementia. Regardless,
our study helps to supports these findings.
A few mechanisms could help explain the association of dysbiosis-related
medications and dementia. Previous research has found that certain types of
medications and multiple medications have been found to be associated with
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cognitive changes.40–43 Additionally, these medications can cause dysbiosis.8,44
Studies with differing study designs have demonstrated that antipsychotics and
antihistamines substantially affected the microbiome.19,45 Another study among
older adults showed using multiple medications changes the proportions of
bacteria species and causes dysbiosis.45 Recently, much research has been
focused on understanding how the microbiome may influence dementia.46–48 In a
cross-sectional study, individuals with dementia had a significantly different gut
composition compared to those who did not have dementia.49 Further, the
connection between dysbiosis induced by medications and dementia could be
linked through the microbiome-gut-brain axis.50 Gut microbiome dysbiosis can
cause the axis to become disrupted and cause systemic inflammation.51
Dysbiosis-related systemic inflammation is associated with weakening the bloodbrain-barrier, which promotes neuroinflammation and is associated with
neurodegeneration and dementia.14,51–53 Additionally, the gut becomes more
permeable and allows bacteria to leave the gut, which can then cross the
weakened blood-brain-barrier; these bacteria can aggregate beta proteins into
plaques, which is associated with Alzheimer’s disease.54,55
Our study demonstrates some strengths. First, our study had 12 years of
follow-up among a nationally representative cohort. Additionally, cognitive
outcomes were imputed for missing variables. Although there we have
demonstrated some strengths, there are limitations to note. First, there may have
been some unmeasured confounding that could bias the results; however, we
found through our E-value that unmeasured confounding would need to be an
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odds ratio of about 14.3 for those who were cognitively normal and 18.05 for
those who had MCI with both the exposure and outcome to cause the findings of
those taking antipsychotics to become null. Among those that had MCI, the Evalue for the association between using an antihistamine was 11.24, suggesting
large unmeasured confounding is needed to change our results. Further, large
unmeasured confounding is needed for taking two or more medications (5.21),
but small-to-moderate unmeasured confounding (1.36) would be needed to make
the interaction between taking two or more medications with time change to a
null result. Further, in a sensitivity analysis when antipsychotics were removed
from the grouped medications variable both the main effect of taking two or more
medications and the interactions between the taking two or medications and time
were insignificant; however, when removing both SSRIs and TCAs the main
effect changed to insignificant but the interaction with time remained significant.
These sensitivity findings may be caused by individuals with mental illness are at
higher risk of dementia which could lead to confounding by indication. The
medication dosage, duration before the study, and duration after the year 2005
were not captured in the study's survey, which limited our analysis to compare
users and non-users only at baseline. We did not directly measure the impact of
these medications on the microbiome, but previous studies have found them to
be associated with dysbiosis.8,19,24 Another potential limitation is that we cannot
be certain that cognitive decline did not begin before individuals used these
medications. Lastly, the cognitive outcomes and the categorization of dementia
was based on a cognitive test that ranged from 0-27, which could lead to
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misclassification. However, these categories have been found to correctly
classify about 74-79% of individuals compared to the more rigorous clinical
neuropsychological battery in previous studies.23 Lastly, there is potential for
informative censoring. That is, those were loss to follow up due to death were
more likely to use more medications and have higher risk of dementia. This may
explain the decreasing magnitude of the association between the using multiple
medications and dementia over time.
Among a large sample of older United States adults, we found individuals
who used antipsychotics were more likely to have dementia among those who
were cognitively normal and had MCI at baseline. Additionally, among those who
had MCI at baseline, individuals who took antihistamines were less likely to have
dementia, while those who took two or more medications were more likely to
have dementia. Of importance, physicians should be more mindful of these
findings when considering prescribing antipsychotics or if an individual is taking
multiple dysbiosis-related medications. This is not to say that individuals in need
of these medications should not have them prescribed, but rather for healthcare
providers to understand and track cognitive changes of patients while taking
these medications. To help understand how medications influence the gut
microbiome and subsequently cognitive changes, future research should
longitudinally track older adult's prescription utilization, gut microbiome
composition, and cognitive function through a cohort study.
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Table 6.1. Weighted Baseline Demographic and Health Characteristics of the
Analytic Sample
Mild
Cognitively
All
Cognitive
Normal
(n=3,594)
Impairmen
(n=2,805)
t (n=789)
pVariable
% (n) or Mean (SE)
value
68.61
<0.00
65.44 (0.17)
Age
64.69 (0.19)
(0.40)
1
Race
88.19%
90.71%
White
(3,011)
(2,442)
77.57 (568) <0.00
8.12% (456) 6.46% (283) 15.06 (173)
Black
1
3.70% (127)
Other
2.82% (79)
7.37 (48)
Gender
57.18%
57.04%
Female
(2,130)
(1,662)
57.75 (468)
0.763
42.82%
42.96%
Male
(1,464)
(1,143)
42.25 (321)
Education
Less than
21.25%
High15.78%
44.06%
(920)
school
(512)
(399)
5.52% (183) 5.50% (140) 5.60% (43)
GED
<0.00
High33.79%
34.67%
30.10%
1
school
(1,217)
(1,000)
(217)
Some
19.57%
21.02%
13.53%
college
(660)
(571)
(89)
College
19.87%
23.02%
and above
(613)
(571)
6.70% (41)
Number of
<0.00
1.51 (0.02)
chronic
1
conditions
1.45 (0.03)
1.76 (0.05)
27.53
27.55 (0.11)
0.914
BMI
27.55 (0.13)
(0.24)
Ever smoker
41.81%
41.54%
42.98%
No
(1,419)
(1,099)
(320)
0.551
58.19%
58.46%
57.02%
Yes
(2,883)
(1,477)
(406)
Number of
<0.00
alcoholic
0.64 (0.02)
1
drinks
0.68 (0.03)
0.45 (0.05)
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Number of
depressive
symptoms
Antibiotics

1.47 (0.04)

Proton Pump Inhibitors
Antidepressa
nts
SSRI
TCA
Antipsychotic
s
Antihistamine
s
Any
medication

2.35% (87)
14.62%
(503)
11.99%
(412)
9.67% (326)
2.51% (91)
1.16% (32)
1.89% (76)

Zero

72.49%
(2,639)
23..15%
(807)

1.34 (0.04)
2.49% (72)
14.26%
(394)
11.85%
(319)
9.54% (252)
2.55% (72)

2.09 (0.10)
1.74% (15)
16.12%
(109)
12.55%
(93)
10.19%
(74)
2.36% (19)

0.84% (17)

2.52% (15)

1.71% (57)

2.63% (19)

73.04%
(2,066)
22.80%
(623)

70.17%
(573)
24.62%
(184)

<0.00
1
0.248
0.294

0.655
0.800
0.004
0.207

0.366
One
Two or
4.36% (148)
more
4.15% (116) 5.21% (32)
Note: BMI = body mass index; SSRI = selective serotonin reuptake inhibitor; TCA
= tricyclic antidepressant.
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Table 6.2. Unadjusted and Adjusted Generalized Linear Mixed Model Results of Medications on Dementia

Medication

Antidepressants
SSRI
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TCA
Antibiotics
Antihistamines
Antipsychotics
Proton Pump
Inhibitors
Binary
medication
None
One or
more
One or

Cognitively Healthy
Adjusted
Unadjusted
Odds
Odds Ratios
pRatios
(95%
value
(95%
Confidence
Confidence
Interval)
Interval)
1.37 (0.98,
0.07 1.31 (0.82,
1.92)
0
1.89)
1.51 (1.00,
0.02 1.45 (0.87,
2.17)
8
2.45)
0.74 (0.35,
0.42 0.61 (0.25,
1.55)
7
1.49)
1.07 (0.46,
0.86 0.88 (0.37,
2.49)
9
2.11)
2.14 (1.10,
0.02 1.85 (0.83,
4.17)
6
4.12)
2.97 (0.75,
0.12 7.41 (2.03,
11.84)
2
27.03)
1.02 (0.72,
0.91 1.00 (0.69,
1.44)
7
1.45)

Ref
1.49 (0.99,
2.25)
0.98 (0.95,

***
0.05
7
0.38

Ref
1.48 (0.92,
2.37)
0.98 (0.93,

Mild Cognitive Impairment

pvalue

Unadjusted
Odds Ratios
(95%
Confidence
Interval)

0.31
0
0.15
1
0.27
6
0.77
2
0.13
0
0.00
2
0.99
2

1.32 (0.83,
2.09)
1.46 (1.07,
2.00)
0.75 (0.37,
1.50)
0.35 (0.10,
1.18)
0.25 (0.21,
0.28)
3.90 (2.39,
6.36)
0.90 (0.58,
1.39)

***
0.10
3
0.28

Ref
1.09 (0.73,
1.65)
0.97 (0.93,

pvalue

0.239
0.151
0.415
0.091
0.002
<0.00
1
0.643

***
0.668
0.258

Adjusted
Odds Ratios
(95%
Confidence
Interval)
1.37 (0.80,
2.36)
1.70 (0.95,
3.07)
0.54 (0.20,
1.49)
0.30 (0.06,
1.55)
0.17 (0.06,
0.53)
9.28 (2.00,
21.52)
0.80 (0.50,
1.27)

Ref
1.28 (0.76,
2.14)
0.95 (0.89,

pvalue

0.255
0.076
0.234
0.150
0.002
<0.00
1
0.339

***
0.354
0.067

more*tim
e

1.02)

7

1.02)

9

1.02)

Ref
1.42 (0.91,
2.24)
0.99 (0.95,
1.03)
1.90 (0.90,
3.99)

***
0.12
6
0.56
7
0.09
1

Ref
1.36 (0.82,
2.27)
0.98 (0.94,
1.03)
2.27 (1.00,
5.64)

***
0.23
7
0.48
3
0.05
0

Ref
0.97 (0.62,
1.52)
0.99 (0.94,
1.04)
1.83 (0.82,
4.09)

1.00)

Any
medication
None
One
One*time

***
0.909
0.661

Ref
1.09 (0.63,
1.88)
0.96 (0.90,
1.03)
2.88 (1.08,
7.67)

***
0.771
0.260
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Two or
0.139
0.034
more
Two or
0.96 (0.88,
0.32 0.94 (0.85, 0.20
0.90 (0.84,
0.86 (0.80,
<0.00
more*tim
0.007
1.04)
4
1.03)
2
0.97)
0.93)
1
e
Note: SSRI = selective serotonin reuptake inhibitor; TCA = tricyclic antidepressant; All models were adjusted for age,
race, gender, education, number of chronic conditions, body mass index, ever smoked, and number of alcoholic drinks
consumed; Multiple medication measure, antidepressants, SSRIs, and TCAs additionally were adjusted for depressive
symptoms

Table 6.3. Adjusted Generalized Linear Mixed Model Results of Taking Two or
More Medications' Association with Dementia at Each Year Among Those with
Mild Cognitive Impairment at Baseline
Adjusted Odds Ratios

95% Confidence
Interval

p-value

2004 (Baseline)

2.88

1.08 - 7.67

0.034

2006

2.49

0.94 - 6.55

0.065

2008

2.15

0.82 -5.64

0.120

2010

1.86

0.71 0 4.88

0.210

2012

1.60

0.60 - 4.25

0.343

2014

1.38

0.51 - 3.72

0.520

Year

2016
1.20
0.43 -3.28
0.730
Note: Adjusted for age, race, gender, education, number of chronic conditions,
body mass index, ever smoked, number of alcoholic drinks consumed, and
depressive symptoms
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CHAPTER 7
SUMMARY
7.1 SUMMARY
The findings from this dissertation have provided further insight into how
dysbiosis-related medications (DRM) and the association with cognitive decline,
mild cognitive impairment, and dementia in a nationally representative sample of
adults 51 and older in the United States. To examine how individuals with
different cognitive statuses may progress to dementia, we further looked at how
baseline cognitive status was associated with dementia. Furthermore, we
examined how inflammation may be associated with the association of DRM and
cognitive scores, which was done with a causal medication analysis.
Overall, there are some critical findings through each chapter that weave a
narrative for many aspects of cognitive decline, cognitive function, and dementia
among older adults in the Untied States. After examining the longitudinal
association of specific DRM and grouped medications with cognitive performance
to further expand the literature on how medications may be associated with
cognitive outcomes over time, we helped to confirm previous studies research on
the topic. That being, SSRI antidepressants, antipsychotics, and antihistamines
were associated with greater cognitive outcomes. More specifically, participants
using SSRIs and antipsychotics were more likely to have MCI and dementia. In
line with previous research, we found that using two or more medications was
greater cognitive decline, MCI, and dementia. Additionally, we provided a more
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in-depth picture by which DRM may be associated with cognitive scores. By
examining the association between specific and grouped medications and
cognitive scores and whether inflammation may mediate this association, we
were better able to decompose a specific mechanism – inflammation – in relation
to medications and cognitive outcomes. Our study did not provide any statistically
significant results. Participants using SSRIs and antipsychotics had lower
cognitive scores on average compared to non-users of SSRIs and
antipsychotics. This study is among the first to examine the role of inflammation
on the association between medications associated with dysbiosis and cognitive
scores. Lastly, we explored how medications may differentially impact the
association of those that were cognitively normal and had MCI at baseline with
having dementia. We found that in a nationally representative cohort of older
United States adults, the use of antipsychotics among those who were
cognitively normal and had MCI at baseline was associated with greater odds of
dementia but did not find evidence of these odds changing over time.
Additionally, we found that among those who had MCI, individuals who used
antihistamine showed lower odds of dementia compared to non-users but did not
find evidence of these odds changing over time. We additionally found evidence
that those who had MCI and were taking two or more medications had greater
odds of dementia; however, these odds decreased over time compared to those
not taking dysbiosis-related medications.
These findings have important medical and public health implications that
should be considered moving forward. Through the findings from this dissertation
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health care providers should consider the impact of medications on the
microbiome and how that influences the health of their patients. For example, an
individual with major depressive disorder that has been on medications for years
may experiences changes in the microbiome from the medications they have
been prescribed. If possible, their medical care provider should monitor their
patients’ microbiome or health outcomes, such as cognitive changes, related to
dysbiosis. If changes are found, the health care provider should consider
changing medications to one that does not influence changes in the microbiome
or provide an intervention, such as probiotics or fecal microbiota transplantation,
that may help to “heal” the microbiome. Another impact on the medical field is
understanding, translating, and providing health literacy to patients and their
caregivers to help them understand what the microbiome is and how changes to
it may influence health changes. By doing so, the patient and their caregiver can
better understand the medications prescribed a potential impact on the health of
the patient. Lastly, these findings may influence future research in the field. One
area of future research should expand upon these findings and develop a cohort
of mild-to-older aged adults. Through follow up of these older adults, researchers
can monitor the individual’s microbiome, potential influences on the microbiome,
biomarkers, and health comes related to cognitive changes. Through this cohort,
researchers will better understand that longitudinal changes of the microbiome,
what influences these changes, and how these changes may impact cognitive
health among adults.
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Among a large sample of older United States adults, we found individuals
who used antipsychotics were more likely to have dementia among those who
were cognitively normal and had MCI at baseline. Additionally, among those who
had MCI at baseline, individuals who took antihistamines were less likely to have
dementia, while those who took two or more medications were more likely to
have dementia. Of importance, physicians should be more mindful of these
findings when considering prescribing antipsychotics or if an individual is taking
multiple dysbiosis-related medications. This is not to say that individuals in need
of these medications should not have them prescribed, but rather for healthcare
providers to understand and track cognitive changes of patients while taking
these medications. To help understand how medications influence the gut
microbiome and subsequently cognitive changes, future research should
longitudinally track older adult's prescription utilization, gut microbiome
composition, and cognitive function through a cohort study.
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APPENDIX A
DYSBIOSIS-RELATED MEDICATION TYPES AND GENERIC NAMES
Table A.1 Type of medications and corresponding generic names
Medication Type
Generic Names
Antidepressants
Selective
serotonin
Escitalopram, Citalopram, Fluoxetine,
reuptake
Paroxetine, Sertraline
inhibitors
Amoxapine, Desipramine, Trimipramine,
Tricyclic
Clomipramine, Protriptyline, Amitriptyline,
antidepressants
Nortriptyline, Imipramine, Doxepin
Amoxicillin, Ampicillin, Bacitracin,
Cefotaxime, Chloramphenicol, Ciprofloxacin,
Clarithromycin, Clindamycin, Clindamycin,
Erythromycin, Gentamicin, Meropenem,
Metronidazole, Neomycin, Rifampicin,
Streptomycin, Ticarcillin, Tigecycline,
Vancomycin
Antibiotics

Proton Pump Inhibitors

Antipsychotics

Antihistamines

Omeprazole, Esomeprazole, Lansoprazole,
Rabeprazole, Pantoprazole,
Dexlansoprazole
Clozapine, Olanzapine, Risperidone,
Quetiapine, Asenapine, Ziprasidone,
Lurasidone, Aripiprazole, Paliperidone,
Iloperidone
Chlorpheniramine, Cyproheptadine,
Doxylamine, Hydroxyzine, Dimenhydrinate,
Diphenhydramine, Meclizine, Promethazine
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